temozolomide has been researched along with Disease Models, Animal in 148 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We searched three online databases to systematically identify publications testing temozolomide in animal models of glioma." | 8.89 | Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted? ( Egan, KJ; Hirst, TC; Macleod, MR; Sena, ES; Vesterinen, HM; Whittle, IR, 2013) |
| " Treatment of patients suffering from relapsed/refractory glioblastoma (GBM) with a combination of depatux-m and temozolomide (TMZ) tended to increase overall survival." | 8.02 | Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR. ( Alvey, C; Anderson, M; Ansell, P; Boghaert, ER; Falls, HD; Mishra, S; Mitten, MJ; Oleksijew, A; Palma, J; Phillips, AC; Reilly, EB; Vaidya, KS; Zelaya-Lazo, AL, 2021) |
| " However, the alterations in gut microbiota observed during glioma growth and temozolomide (TMZ) therapy remain poorly understood." | 8.02 | Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma. ( Jiang, Y; Jin, XQ; Li, J; Li, XC; Li, YR; Li, ZQ; Ma, C; Wang, ZF; Wu, BS; Yao, J, 2021) |
| "Our data revealed (i) a clinical association of the EMT-like process with glioma malignancy and a poor survival and (ii) an anticancer and temozolomide sensitizing effect of rabeprazole by repressing EMT." | 8.02 | Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition. ( Babu, D; Mudiraj, A; Panigrahi, M; Prakash Babu, P; Y B V K, C; Yadav, N, 2021) |
| "Following captopril treatment, MMP-2 protein expression and migratory capabilities of 9 L gliosarcoma cells were assessed in vitro via western blots and scratch wound assays, respectively." | 8.02 | Captopril inhibits Matrix Metalloproteinase-2 and extends survival as a temozolomide adjuvant in an intracranial gliosarcoma model. ( Brem, H; Casaos, J; Huq, S; Mangraviti, A; Paldor, I; Perdomo-Pantoja, A; Pinheiro, L; Tyler, B; Vigilar, V; Wang, Y; Witham, TF, 2021) |
| "To some extent, Si wei xiao xiu yin combined with temozolomide can inhibit the growth of subcutaneous xenografts in glioma nude mice." | 7.96 | New advances on the inhibition of Siwei Xiaoliuyin combined with Temozolomide in glioma based on the regulatory mechanism of miRNA21/221. ( Chen, H; Chen, Y; Li, C; Sharma, A; Sharma, HS; Tan, Q; Xie, C; Yang, Y; Zhan, W; Zhang, Z, 2020) |
| "To develop an innovative delivery system for temozolomide (TMZ) in solid lipid nanoparticles (SLN), which has been preliminarily investigated for the treatment of melanoma." | 7.88 | Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies. ( Annovazzi, L; Battaglia, L; Biasibetti, E; Boggio, E; Cangemi, L; Capucchio, MT; Clemente, N; Dianzani, C; Dianzani, U; Ferrara, B; Gigliotti, CL; Mellai, M; Miglio, G; Muntoni, E; Schiffer, D, 2018) |
| "Temozolomide (TMZ) is the most frequent adjuvant chemotherapy drug in gliomas." | 7.88 | Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model. ( Dai, B; Li, J; Qi, N; Zhang, G, 2018) |
| "The combination drug treatment of mannitol and temozolomide allowed for the efficient delivery of hUC-MSC-derived microvesicles into the brain in a chronic stroke rat model." | 7.88 | The combination of mannitol and temozolomide increases the effectiveness of stem cell treatment in a chronic stroke model. ( Choi, C; Kang, SH; Kim, HM; Kim, HT; Kim, NK; Kim, OJ; Oh, SH; Park, J; Shon, J, 2018) |
| "Here we evaluated whether glioma sensitive or resistant to temozolomide (TMZ) modulate macrophage polarization and inflammatory pathways associated." | 7.85 | Glioma sensitive or chemoresistant to temozolomide differentially modulate macrophage protumor activities. ( Azambuja, JH; Beira, FT; Braganhol, E; da Silveira, EF; de Carvalho, TR; do Couto, CT; Oliveira, PS; Pacheco, S; Spanevello, RM; Stefanello, FM, 2017) |
| "Temozolomide-resistant (TMZ-R) glioblastoma is very difficult to treat, and a novel approach to overcome resistance is needed." | 7.85 | Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line. ( Akiyama, Y; Asai, A; Ashizawa, T; Hayashi, N; Iizuka, A; Kondou, R; Mitsuya, K; Miyata, H; Nakasu, Y; Nonomura, C; Sugino, T; Urakami, K; Yamaguchi, K, 2017) |
| "The current standard of care for glioblastoma (GBM) is surgical resection, radiotherapy, and treatment with temozolomide (TMZ)." | 7.83 | MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival. ( Chaumeil, MM; Eriksson, P; Phillips, JJ; Radoul, M; Ronen, SM; Wang, AS, 2016) |
| "Despite the use of ionizing radiation (IR) and temozolomide (TMZ), outcome for glioblastoma (GBM) patients remains dismal." | 7.83 | Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model. ( Chenevert, TL; Galbán, CJ; Galbán, S; Heist, KA; Holland, EC; Lemasson, B; Li, Y; Rehemtulla, A; Ross, BD; Tsein, C; Wang, H; Zhu, Y, 2016) |
| "Temozolomide (TMZ) is the main chemotherapeutic drug utilized for the treatment of glioblastoma multiforme (GMB), however, drug resistance often leads to tumor recurrence and poor outcomes." | 7.83 | Expression of dynein, cytoplasmic 2, heavy chain 1 (DHC2) associated with glioblastoma cell resistance to temozolomide. ( Chen, Z; Feng, W; He, M; Lei, B; Li, H; Liu, Y; Lu, Y; Qi, S; Sun, X; Wang, H; Xiang, W; Zhao, L, 2016) |
| "Temozolomide (TMZ) is an alkylating agent that has become the mainstay treatment of the most malignant brain cancer, glioblastoma multiforme (GBM)." | 7.83 | Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems. ( Assoulin, M; Constantini, S; Daniels, D; Fisher, T; Freedman, S; Guez, D; Last, D; Mardor, Y; Mehrian-Shai, R; Moshe, I; Pismenyuk, T; Reichardt, JK; Simon, AJ; Toren, A; Yalon, M, 2016) |
| " As poor differentiation and low apoptosis are closely associated with poor survival rates and a poor response to radio/chemotherapy in patients with cancer, the prognostic value of Dec1 expression was examined in the present study and its correlation with response to temozolomide (TMZ) chemotherapy was analyzed in patients with glioma." | 7.83 | Dec1 expression predicts prognosis and the response to temozolomide chemotherapy in patients with glioma. ( Bian, H; Huang, Y; Li, XM; Lin, W; Wang, J; Yao, L; Yin, AA; Zhang, J; Zhang, W; Zhang, X, 2016) |
| "Development of temozolomide (TMZ) resistance contributes to the poor prognosis for glioblastoma multiforme (GBM) patients." | 7.81 | A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. ( Chang, EH; Kim, E; Kim, SS; Pirollo, KF; Rait, A, 2015) |
| "The alkylating agent temozolomide (TMZ) represents an important component of current melanoma therapy, but overexpression of O6-methyl-guanine DNA methyltransferase (MGMT) in tumor cells confers resistance to TMZ and impairs therapeutic outcome." | 7.81 | A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo. ( Chen, TC; Cho, HY; Hofman, FM; Jhaveri, N; Nguyen, J; Rosenstein-Sisson, R; Schönthal, AH; Wang, W, 2015) |
| "Wee1 regulates key DNA damage checkpoints, and in this study, the efficacy of the Wee1 inhibitor MK-1775 was evaluated in glioblastoma multiforme (GBM) xenograft models alone and in combination with radiation and/or temozolomide." | 7.81 | The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. ( Agar, NY; Bakken, KK; Calligaris, D; Carlson, BL; Decker, PA; Eckel-Passow, JE; Elmquist, WF; Evans, DL; Gupta, SK; Iyekegbe, DO; Lou, Z; Ma, B; Mueller, D; Pokorny, JL; Pucci, V; Sarkaria, JN; Schroeder, MA; Shumway, SD, 2015) |
| " Chemotherapy has been observed to prolong overall survival rate and temozolomide (TMZ), a promising chemotherapeutic agent for treating glioblastoma (GBM), possesses the most effective clinical activity at present, although drug resistance limits its clinical outcome." | 7.81 | p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis. ( Fan, Y; Guo, G; Li, Q; Lian, S; Liu, X; Miao, W; Wang, H; Wang, S; Wang, X; Yang, X, 2015) |
| "The aim of this study is to investigate the inhibitory effects of 2T-P400, a derivative of temozolomide (TMZ), on glioma growth." | 7.80 | The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection. ( Dong, J; Li, R; Tang, D; Wang, L; Wu, J; Zhang, J, 2014) |
| " This study employed intracranial human glioma models to evaluate the effect of BEV alone and in combination with temozolomide (TMZ) and/or radiation therapy (XRT) on overall survival." | 7.80 | Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models. ( Blakeley, JO; Brastianos, H; Brem, H; Goodwin, RC; Grossman, R; Hwang, L; Lal, B; Mangraviti, A; Tyler, B; Wicks, RT; Zadnik, P, 2014) |
| "Ependymoma SC lines were highly sensitive to temozolomide and etoposide in vitro, but only temozolomide impaired tumor-initiation properties." | 7.80 | Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models. ( Arena, V; Binda, E; Lamorte, G; Meco, D; Riccardi, R; Servidei, T, 2014) |
| "The purpose of this study is to assess the preclinical therapeutic efficacy of magnetic resonance imaging (MRI)-monitored focused ultrasound (FUS)-induced blood-brain barrier (BBB) disruption to enhance Temozolomide (TMZ) delivery for improving Glioblastoma Multiforme (GBM) treatment." | 7.79 | Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study. ( Chen, PY; Chu, PC; Feng, LY; Hsu, PW; Huang, CY; Lee, PY; Liu, HL; Lu, YJ; Tsai, HC; Tseng, IC; Wang, HY; Wei, KC; Yen, TC, 2013) |
| " In previous studies the alkylating agent temozolomide (TMZ) incorporated into a polymer, pCPP:SA, also for local delivery, and OncoGel were individually shown to increase efficacy in a rat glioma model." | 7.79 | Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model. ( Brem, H; Eberhart, CG; Fowers, KD; Hwang, L; Li, KW; Okonma, S; Recinos, VR; Tyler, BM; Vellimana, AK; Zhang, Y, 2013) |
| "The combination of hyperbaric oxygen with temozolomide produced an important reduction in glioma growth and effective approach to the treatment of glioblastoma." | 7.78 | Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model. ( Bilir, A; Bozkurt, ER; Dagıstan, Y; Karaca, I; Ozar, E; Toklu, A; Yagmurlu, K, 2012) |
| "The alkylating agent temozolomide, in combination with surgery and radiation, is the current standard of care for patients with glioblastoma." | 7.77 | Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. ( Chen, TC; Golden, EB; Hofman, FM; Louie, SG; Schönthal, AH; Sivakumar, W; Thomas, S; Wang, W, 2011) |
| "In this study, we investigated the potential of combined treatment with temozolomide (TMZ) chemotherapy and tumor antigen-pulsed dendritic cells (DCs) and the underlying immunological factors of TMZ chemoimmunotherapy with an intracranial GL26 glioma animal model." | 7.76 | Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. ( Chung, DS; Hong, YK; Kim, CH; Kim, CK; Kim, TG; Park, JS; Park, SD, 2010) |
| "We hypothesized that the observed clinical synergy of orally administered TMZ and carmustine (BCNU) wafers would translate into even greater effectiveness with the local delivery of BCNU and TMZ and the addition of radiotherapy in animal models of malignant glioma." | 7.76 | Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. ( Bekelis, K; Brem, H; Li, KW; Recinos, VR; Sunshine, SB; Tyler, BM; Vellimana, A, 2010) |
| "Temozolomide (TM) has anti-tumor activity in patients with malignant glioma." | 7.76 | Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Liu, JM; Tang, GS; Wang, Y; Yue, ZJ; Zhang, H; Zhang, YH, 2010) |
| "We have completed in vivo safety and efficacy studies of the use of a novel drug delivery system, a gel matrix-temozolomide formulation that is injected intracranially into the post-resection cavity, as a candidate for glioma therapy." | 7.75 | Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection. ( Akbar, U; Duntsch, C; Jones, T; Michael, M; Shukla, A; Sun, Y; Winestone, J, 2009) |
| " In this study, the authors investigate the nature of the SP phenotype in 2 glioma cell lines, U87MG and T98G, and their response to temozolomide." | 7.74 | Characterization of a side population of astrocytoma cells in response to temozolomide. ( Ang, BT; Chong, KH; Chua, C; See, SJ; Tang, C; Wong, MC; Zaiden, N, 2008) |
| "In this study, we investigated the mechanisms by which temozolomide enhances radiation response in glioblastoma cells." | 7.73 | Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. ( Aldape, K; Black, PM; Chakravarti, A; Erkkinen, MG; Gilbert, MR; Loeffler, JS; Mehta, M; Nestler, U; Stupp, R, 2006) |
| "Isolated limb infusion (ILI) with temozolomide (TMZ), a novel methylating agent, was performed using a nude rat bearing human melanoma xenograft." | 7.72 | Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. ( Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T, 2004) |
| " These results form part of the basis for the translation of the therapy to patients with GBM but the dosing and timing of delivery will have to be explored in depth both experimentally and clinically." | 5.56 | Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas. ( Darabi, A; Enríquez Pérez, J; Kopecky, J; Siesjö, P; Visse, E, 2020) |
| "Olaparib treatment reduced cell viability and cell migration in a dose-dependent manner in vitro." | 5.56 | Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo. ( Desar, IME; Fleuren, EDG; Flucke, UE; Hillebrandt-Roeffen, MHS; Mentzel, T; Shipley, J; van Bree, NFHN; van der Graaf, WTA; van Erp, AEM; van Houdt, L; Versleijen-Jonkers, YMH, 2020) |
| "Glioblastomas are characterized by amplification of EGFR." | 5.46 | Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma. ( Asuthkar, S; Bach, SE; Guda, MR; Lathia, JD; Sahu, K; Tsung, AJ; Tuszynski, J; Velpula, KK, 2017) |
| "Glioblastoma is one of the most lethal cancers in humans, and with existing therapy, survival remains at 14." | 5.43 | Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. ( Aman, A; Cairncross, JG; Dang, NH; Datti, A; Easaw, JC; Grinshtein, N; Hao, X; Kaplan, DR; King, JC; Luchman, A; Lun, X; Robbins, SM; Senger, DL; Uehling, D; Wang, X; Weiss, S; Wells, JC; Wrana, JL, 2016) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic agent but the efficacy is limited by intrinsic and acquired resistance in GBM." | 5.40 | Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells. ( Chen, YS; Chen, ZP; Guan, S; Guo, CC; Li, WP; Li, WY; Mou, YG; Sai, K; Wang, J; Yang, QY, 2014) |
| "Previously, it has been shown that treatment of glioma cells with temozolomide (TMZ) and radiation (XRT) induces the expression of metalloproteinase 14 (MMP14)." | 5.39 | Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas. ( Auffinger, B; Baryshnikov, AY; Borovjagin, A; Dey, M; Guo, D; Han, Y; Kim, CK; Lesniak, MS; Pytel, P; Sarvaiya, P; Thaci, B; Ulasov, I; Yi, R; Zhang, L, 2013) |
| "Malignant gliomas are highly lethal tumors resistant to current therapies." | 5.37 | Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. ( Barnes, JW; Chaponis, D; Dellagatta, JL; Fast, E; Greene, ER; Kesari, S; Kieran, MW; Kung, AL; Panagrahy, D; Ramakrishna, N; Sauvageot, C; Stiles, C; Wen, PY, 2011) |
| "Indeed melanomas have proven resistant to apoptosis (type I programmed cell death (PCD)) and consequently to most chemotherapy and immunotherapy." | 5.34 | Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. ( De Neve, N; Gras, T; Kiss, R; Le Mercier, M; Lefranc, F; Mathieu, V; Roland, I; Sauvage, S, 2007) |
| "Temozolomide treatment of high-grade tv-a gliomas provided a 14-day growth delay compared with vehicle controls." | 5.34 | Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. ( Hambardzumyan, D; Holland, EC; Kreger, AR; Leopold, WR; McConville, P; Moody, JB; Rehemtulla, A; Ross, BD; Woolliscroft, MJ, 2007) |
| "Gliomas are primary brain tumors associated with a poor prognosis partly due to resistance to conventional therapies." | 5.33 | Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model. ( Itasaka, S; Kim, JT; Lee, JI; Nam, DH, 2006) |
| "Tamoxifen and hypericin were able to greatly increase the growth-inhibitory and apoptosis-stimulatory potency of temozolomide via the downregulation of critical cell cycle-regulatory and prosurvival components." | 5.33 | Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin. ( Chen, TC; Gupta, V; Hofman, FM; Kardosh, A; Liebes, LF; Schönthal, AH; Su, YS; Wang, W, 2006) |
| " In contrast, the cytotoxic drug temozolomide, when used in combination with HIF-1alpha knockdown, exhibited a superadditive and likely synergistic therapeutic effect compared with the monotherapy of either treatment alone in the D54MG glioma model." | 5.33 | Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. ( Albert, DH; Fesik, SW; Li, L; Lin, X; Shen, Y; Shoemaker, AR, 2006) |
| " It is proposed that the net balance of antiangiogenic drug-mediated pharmacodynamic actions will determine how drug disposition in tumors may be affected." | 5.32 | Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. ( Gallo, JM; Guo, P; Li, S; Ma, J; Reed, K, 2003) |
| "We searched three online databases to systematically identify publications testing temozolomide in animal models of glioma." | 4.89 | Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted? ( Egan, KJ; Hirst, TC; Macleod, MR; Sena, ES; Vesterinen, HM; Whittle, IR, 2013) |
| "Patients with glioblastoma (GBM) are treated with radiotherapy (RT) and temozolomide (TMZ)." | 4.12 | Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models. ( Campian, JL; Chheda, MG; Ferrando-Martinez, S; Ghosh, S; Hallahan, D; Hu, T; Jash, A; Kapoor, V; Lee, BH; Mahadevan, A; Page, L; Rifai, K; Thotala, D; Thotala, S; Wolfarth, AA; Yan, R; Yang, SH, 2022) |
| " Treatment of patients suffering from relapsed/refractory glioblastoma (GBM) with a combination of depatux-m and temozolomide (TMZ) tended to increase overall survival." | 4.02 | Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR. ( Alvey, C; Anderson, M; Ansell, P; Boghaert, ER; Falls, HD; Mishra, S; Mitten, MJ; Oleksijew, A; Palma, J; Phillips, AC; Reilly, EB; Vaidya, KS; Zelaya-Lazo, AL, 2021) |
| " However, the alterations in gut microbiota observed during glioma growth and temozolomide (TMZ) therapy remain poorly understood." | 4.02 | Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma. ( Jiang, Y; Jin, XQ; Li, J; Li, XC; Li, YR; Li, ZQ; Ma, C; Wang, ZF; Wu, BS; Yao, J, 2021) |
| "Our data revealed (i) a clinical association of the EMT-like process with glioma malignancy and a poor survival and (ii) an anticancer and temozolomide sensitizing effect of rabeprazole by repressing EMT." | 4.02 | Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition. ( Babu, D; Mudiraj, A; Panigrahi, M; Prakash Babu, P; Y B V K, C; Yadav, N, 2021) |
| "Following captopril treatment, MMP-2 protein expression and migratory capabilities of 9 L gliosarcoma cells were assessed in vitro via western blots and scratch wound assays, respectively." | 4.02 | Captopril inhibits Matrix Metalloproteinase-2 and extends survival as a temozolomide adjuvant in an intracranial gliosarcoma model. ( Brem, H; Casaos, J; Huq, S; Mangraviti, A; Paldor, I; Perdomo-Pantoja, A; Pinheiro, L; Tyler, B; Vigilar, V; Wang, Y; Witham, TF, 2021) |
| "To some extent, Si wei xiao xiu yin combined with temozolomide can inhibit the growth of subcutaneous xenografts in glioma nude mice." | 3.96 | New advances on the inhibition of Siwei Xiaoliuyin combined with Temozolomide in glioma based on the regulatory mechanism of miRNA21/221. ( Chen, H; Chen, Y; Li, C; Sharma, A; Sharma, HS; Tan, Q; Xie, C; Yang, Y; Zhan, W; Zhang, Z, 2020) |
| "To develop an innovative delivery system for temozolomide (TMZ) in solid lipid nanoparticles (SLN), which has been preliminarily investigated for the treatment of melanoma." | 3.88 | Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies. ( Annovazzi, L; Battaglia, L; Biasibetti, E; Boggio, E; Cangemi, L; Capucchio, MT; Clemente, N; Dianzani, C; Dianzani, U; Ferrara, B; Gigliotti, CL; Mellai, M; Miglio, G; Muntoni, E; Schiffer, D, 2018) |
| "Temozolomide (TMZ) is the most frequent adjuvant chemotherapy drug in gliomas." | 3.88 | Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model. ( Dai, B; Li, J; Qi, N; Zhang, G, 2018) |
| "The combination drug treatment of mannitol and temozolomide allowed for the efficient delivery of hUC-MSC-derived microvesicles into the brain in a chronic stroke rat model." | 3.88 | The combination of mannitol and temozolomide increases the effectiveness of stem cell treatment in a chronic stroke model. ( Choi, C; Kang, SH; Kim, HM; Kim, HT; Kim, NK; Kim, OJ; Oh, SH; Park, J; Shon, J, 2018) |
| "Here we evaluated whether glioma sensitive or resistant to temozolomide (TMZ) modulate macrophage polarization and inflammatory pathways associated." | 3.85 | Glioma sensitive or chemoresistant to temozolomide differentially modulate macrophage protumor activities. ( Azambuja, JH; Beira, FT; Braganhol, E; da Silveira, EF; de Carvalho, TR; do Couto, CT; Oliveira, PS; Pacheco, S; Spanevello, RM; Stefanello, FM, 2017) |
| "Temozolomide-resistant (TMZ-R) glioblastoma is very difficult to treat, and a novel approach to overcome resistance is needed." | 3.85 | Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line. ( Akiyama, Y; Asai, A; Ashizawa, T; Hayashi, N; Iizuka, A; Kondou, R; Mitsuya, K; Miyata, H; Nakasu, Y; Nonomura, C; Sugino, T; Urakami, K; Yamaguchi, K, 2017) |
| "The current standard of care for glioblastoma (GBM) is surgical resection, radiotherapy, and treatment with temozolomide (TMZ)." | 3.83 | MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival. ( Chaumeil, MM; Eriksson, P; Phillips, JJ; Radoul, M; Ronen, SM; Wang, AS, 2016) |
| "Despite the use of ionizing radiation (IR) and temozolomide (TMZ), outcome for glioblastoma (GBM) patients remains dismal." | 3.83 | Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model. ( Chenevert, TL; Galbán, CJ; Galbán, S; Heist, KA; Holland, EC; Lemasson, B; Li, Y; Rehemtulla, A; Ross, BD; Tsein, C; Wang, H; Zhu, Y, 2016) |
| "Temozolomide (TMZ) is the main chemotherapeutic drug utilized for the treatment of glioblastoma multiforme (GMB), however, drug resistance often leads to tumor recurrence and poor outcomes." | 3.83 | Expression of dynein, cytoplasmic 2, heavy chain 1 (DHC2) associated with glioblastoma cell resistance to temozolomide. ( Chen, Z; Feng, W; He, M; Lei, B; Li, H; Liu, Y; Lu, Y; Qi, S; Sun, X; Wang, H; Xiang, W; Zhao, L, 2016) |
| "Temozolomide (TMZ) is an alkylating agent that has become the mainstay treatment of the most malignant brain cancer, glioblastoma multiforme (GBM)." | 3.83 | Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems. ( Assoulin, M; Constantini, S; Daniels, D; Fisher, T; Freedman, S; Guez, D; Last, D; Mardor, Y; Mehrian-Shai, R; Moshe, I; Pismenyuk, T; Reichardt, JK; Simon, AJ; Toren, A; Yalon, M, 2016) |
| " By focusing on interactions existing between DNMT3A and DNMT3A-binding protein (D3A-BP), our work identifies the DNMT3A/ISGF3γ interaction such as a biomarker whose the presence level is associated with a poor survival prognosis and with a poor prognosis of response to the conventional chemotherapeutic treatment of glioblastoma multiforme (radiation plus temozolomide)." | 3.83 | Specific Inhibition of DNMT3A/ISGF3γ Interaction Increases the Temozolomide Efficiency to Reduce Tumor Growth. ( Cartron, PF; Cheray, M; Nadaradjane, A; Oliver, L; Pacaud, R; Vallette, FM, 2016) |
| " As poor differentiation and low apoptosis are closely associated with poor survival rates and a poor response to radio/chemotherapy in patients with cancer, the prognostic value of Dec1 expression was examined in the present study and its correlation with response to temozolomide (TMZ) chemotherapy was analyzed in patients with glioma." | 3.83 | Dec1 expression predicts prognosis and the response to temozolomide chemotherapy in patients with glioma. ( Bian, H; Huang, Y; Li, XM; Lin, W; Wang, J; Yao, L; Yin, AA; Zhang, J; Zhang, W; Zhang, X, 2016) |
| "Development of temozolomide (TMZ) resistance contributes to the poor prognosis for glioblastoma multiforme (GBM) patients." | 3.81 | A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. ( Chang, EH; Kim, E; Kim, SS; Pirollo, KF; Rait, A, 2015) |
| "The alkylating agent temozolomide (TMZ) represents an important component of current melanoma therapy, but overexpression of O6-methyl-guanine DNA methyltransferase (MGMT) in tumor cells confers resistance to TMZ and impairs therapeutic outcome." | 3.81 | A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo. ( Chen, TC; Cho, HY; Hofman, FM; Jhaveri, N; Nguyen, J; Rosenstein-Sisson, R; Schönthal, AH; Wang, W, 2015) |
| "Wee1 regulates key DNA damage checkpoints, and in this study, the efficacy of the Wee1 inhibitor MK-1775 was evaluated in glioblastoma multiforme (GBM) xenograft models alone and in combination with radiation and/or temozolomide." | 3.81 | The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. ( Agar, NY; Bakken, KK; Calligaris, D; Carlson, BL; Decker, PA; Eckel-Passow, JE; Elmquist, WF; Evans, DL; Gupta, SK; Iyekegbe, DO; Lou, Z; Ma, B; Mueller, D; Pokorny, JL; Pucci, V; Sarkaria, JN; Schroeder, MA; Shumway, SD, 2015) |
| " Chemotherapy has been observed to prolong overall survival rate and temozolomide (TMZ), a promising chemotherapeutic agent for treating glioblastoma (GBM), possesses the most effective clinical activity at present, although drug resistance limits its clinical outcome." | 3.81 | p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis. ( Fan, Y; Guo, G; Li, Q; Lian, S; Liu, X; Miao, W; Wang, H; Wang, S; Wang, X; Yang, X, 2015) |
| "The aim of this study is to investigate the inhibitory effects of 2T-P400, a derivative of temozolomide (TMZ), on glioma growth." | 3.80 | The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection. ( Dong, J; Li, R; Tang, D; Wang, L; Wu, J; Zhang, J, 2014) |
| " This study employed intracranial human glioma models to evaluate the effect of BEV alone and in combination with temozolomide (TMZ) and/or radiation therapy (XRT) on overall survival." | 3.80 | Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models. ( Blakeley, JO; Brastianos, H; Brem, H; Goodwin, RC; Grossman, R; Hwang, L; Lal, B; Mangraviti, A; Tyler, B; Wicks, RT; Zadnik, P, 2014) |
| " NVP-BEZ235 also sensitized a subset of subcutaneous tumors to temozolomide, a drug routinely used concurrently with ionizing radiation for the treatment of glioblastoma." | 3.80 | Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. ( Bachoo, R; Burma, S; Gao, X; Gil del Alcazar, CR; Habib, AA; Hardebeck, MC; Li, L; Mukherjee, B; Tomimatsu, N; Xie, XJ; Yan, J, 2014) |
| "Wild-type or immunodeficient mice bearing intracranial glioblastoma multiforme or metastatic melanoma were treated with an intratumoral injection of Ad-Flt3L alone or in combination with the conditionally cytotoxic enzyme thymidine kinase (Ad-TK), followed by systemic administration of ganciclovir and temozolomide." | 3.80 | Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models. ( Ahlzadeh, GE; Candolfi, M; Castro, MG; Ghiasi, H; Kamran, N; Lowenstein, PR; Paran, C; Puntel, M; Wibowo, M; Yagiz, K, 2014) |
| "Ependymoma SC lines were highly sensitive to temozolomide and etoposide in vitro, but only temozolomide impaired tumor-initiation properties." | 3.80 | Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models. ( Arena, V; Binda, E; Lamorte, G; Meco, D; Riccardi, R; Servidei, T, 2014) |
| "The purpose of this study is to assess the preclinical therapeutic efficacy of magnetic resonance imaging (MRI)-monitored focused ultrasound (FUS)-induced blood-brain barrier (BBB) disruption to enhance Temozolomide (TMZ) delivery for improving Glioblastoma Multiforme (GBM) treatment." | 3.79 | Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study. ( Chen, PY; Chu, PC; Feng, LY; Hsu, PW; Huang, CY; Lee, PY; Liu, HL; Lu, YJ; Tsai, HC; Tseng, IC; Wang, HY; Wei, KC; Yen, TC, 2013) |
| " In previous studies the alkylating agent temozolomide (TMZ) incorporated into a polymer, pCPP:SA, also for local delivery, and OncoGel were individually shown to increase efficacy in a rat glioma model." | 3.79 | Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model. ( Brem, H; Eberhart, CG; Fowers, KD; Hwang, L; Li, KW; Okonma, S; Recinos, VR; Tyler, BM; Vellimana, AK; Zhang, Y, 2013) |
| "The combination of hyperbaric oxygen with temozolomide produced an important reduction in glioma growth and effective approach to the treatment of glioblastoma." | 3.78 | Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model. ( Bilir, A; Bozkurt, ER; Dagıstan, Y; Karaca, I; Ozar, E; Toklu, A; Yagmurlu, K, 2012) |
| "The alkylating agent temozolomide, in combination with surgery and radiation, is the current standard of care for patients with glioblastoma." | 3.77 | Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. ( Chen, TC; Golden, EB; Hofman, FM; Louie, SG; Schönthal, AH; Sivakumar, W; Thomas, S; Wang, W, 2011) |
| " We investigated the effect of LB1, a small molecule inhibitor of serine/threonine protein phosphatase 2A (PP2A), on its ability to inhibit a low growth fraction and highly drug-resistant solid neuroendocrine tumor, such as metastatic pheochromocytoma (PHEO)." | 3.77 | Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy. ( Bernardo, M; Chiang, J; Lonser, R; Lu, J; Martiniova, L; Pacak, K; Zhuang, Z, 2011) |
| "In this study, we investigated the potential of combined treatment with temozolomide (TMZ) chemotherapy and tumor antigen-pulsed dendritic cells (DCs) and the underlying immunological factors of TMZ chemoimmunotherapy with an intracranial GL26 glioma animal model." | 3.76 | Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. ( Chung, DS; Hong, YK; Kim, CH; Kim, CK; Kim, TG; Park, JS; Park, SD, 2010) |
| "We hypothesized that the observed clinical synergy of orally administered TMZ and carmustine (BCNU) wafers would translate into even greater effectiveness with the local delivery of BCNU and TMZ and the addition of radiotherapy in animal models of malignant glioma." | 3.76 | Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model. ( Bekelis, K; Brem, H; Li, KW; Recinos, VR; Sunshine, SB; Tyler, BM; Vellimana, A, 2010) |
| "Temozolomide (TM) has anti-tumor activity in patients with malignant glioma." | 3.76 | Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model. ( Liu, JM; Tang, GS; Wang, Y; Yue, ZJ; Zhang, H; Zhang, YH, 2010) |
| "We have completed in vivo safety and efficacy studies of the use of a novel drug delivery system, a gel matrix-temozolomide formulation that is injected intracranially into the post-resection cavity, as a candidate for glioma therapy." | 3.75 | Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection. ( Akbar, U; Duntsch, C; Jones, T; Michael, M; Shukla, A; Sun, Y; Winestone, J, 2009) |
| " In this study, the authors investigate the nature of the SP phenotype in 2 glioma cell lines, U87MG and T98G, and their response to temozolomide." | 3.74 | Characterization of a side population of astrocytoma cells in response to temozolomide. ( Ang, BT; Chong, KH; Chua, C; See, SJ; Tang, C; Wong, MC; Zaiden, N, 2008) |
| "In this study, we investigated the mechanisms by which temozolomide enhances radiation response in glioblastoma cells." | 3.73 | Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. ( Aldape, K; Black, PM; Chakravarti, A; Erkkinen, MG; Gilbert, MR; Loeffler, JS; Mehta, M; Nestler, U; Stupp, R, 2006) |
| "Isolated limb infusion (ILI) with temozolomide (TMZ), a novel methylating agent, was performed using a nude rat bearing human melanoma xenograft." | 3.72 | Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. ( Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T, 2004) |
| "High-grade gliomas (WHO grade III anaplastic astrocytoma and grade IV glioblastoma multiforme) are the most common primary tumors in the central nervous system in adults." | 2.45 | High-grade glioma mouse models and their applicability for preclinical testing. ( Beijnen, JH; de Vries, NA; van Tellingen, O, 2009) |
| "High-grade gliomas (HGG) are aggressive brain tumors associated with short median patient survival and limited response to therapies, driving the need to develop tools to improve patient outcomes." | 1.91 | The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors. ( Brochu-Gaudreau, K; Charbonneau, M; Dubois, CM; Fortin, D; Harper, K; Lucien, F; Perreault, A; Roy, LO; Tian, S, 2023) |
| " These results form part of the basis for the translation of the therapy to patients with GBM but the dosing and timing of delivery will have to be explored in depth both experimentally and clinically." | 1.56 | Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas. ( Darabi, A; Enríquez Pérez, J; Kopecky, J; Siesjö, P; Visse, E, 2020) |
| "Olaparib treatment reduced cell viability and cell migration in a dose-dependent manner in vitro." | 1.56 | Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo. ( Desar, IME; Fleuren, EDG; Flucke, UE; Hillebrandt-Roeffen, MHS; Mentzel, T; Shipley, J; van Bree, NFHN; van der Graaf, WTA; van Erp, AEM; van Houdt, L; Versleijen-Jonkers, YMH, 2020) |
| "Gliomas are incurable solid tumors with extremely high relapse rate and definite mortality." | 1.51 | Roscovitine effectively enhances antitumor activity of temozolomide in vitro and in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis. ( Babu, PP; Narne, P; Pandey, V; Ranjan, N, 2019) |
| "Melanoma is a recalcitrant cancer." | 1.48 | Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma. ( Chmielowski, B; Dry, SM; Eckardt, MA; Eilber, FC; Han, Q; Higuchi, T; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, S; Li, Y; Miyake, K; Miyake, M; Nelson, SD; Ohshiro, H; Razmjooei, S; Russell, TA; Singh, AS; Singh, SR; Sugisawa, N; Tan, Y; Unno, M; Wangsiricharoen, S; Zhang, Z; Zhao, M, 2018) |
| "Glioblastomas are characterized by amplification of EGFR." | 1.46 | Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma. ( Asuthkar, S; Bach, SE; Guda, MR; Lathia, JD; Sahu, K; Tsung, AJ; Tuszynski, J; Velpula, KK, 2017) |
| "The current treatment of glioblastoma multiforme (GBM) is limited by the restricted arsenal of agents which effectively cross the blood brain barrier (BBB)." | 1.46 | The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts. ( Adhikari, B; Akers, J; Brandel, MG; Carter, BS; Chen, CC; Deming, T; Futalan, D; Li, J, 2017) |
| "6 μg/day) with negligible leakage into the peripheral blood (<100 ng) rendering ~1000 fold differential drug dosage in tumor versus peripheral blood." | 1.46 | Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma. ( Ashokan, A; Gowd, GS; Junnuthula, VR; Koyakutty, M; Nair, SV; Panikar, D; Peethambaran, R; Ramachandran, R; Thomas, A; Thomas, J; Unni, AK, 2017) |
| " Pharmacokinetic parameters were estimated using non-compartmental analysis." | 1.46 | Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model. ( Cruz, R; Figg, WD; League-Pascual, JC; Lester-McCully, CM; Peer, CJ; Rodgers, L; Ronner, L; Shandilya, S; Warren, KE, 2017) |
| "Glioma is the most frequent primary central nervous system tumor." | 1.46 | β-Elemene Selectively Inhibits the Proliferation of Glioma Stem-Like Cells Through the Downregulation of Notch1. ( Chen, FR; Chen, ZP; Feng, HB; Guo, CC; Jiang, HR; Mei, X; Qu, Y; Sai, K; Wang, J; Yang, QY; Zhang, ZP; Zhao, YY, 2017) |
| "Orthotopic xenograft model of human brain cancer cells is a good preclinical model for evaluation of antitumor compounds." | 1.43 | [Establishment of a glioma orthotopic xenograft model based on imaging technology]. ( Chen, XG; Ji, M; Lai, FF; Lü, YH; Wang, LY, 2016) |
| "Glioblastoma is one of the most lethal cancers in humans, and with existing therapy, survival remains at 14." | 1.43 | Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. ( Aman, A; Cairncross, JG; Dang, NH; Datti, A; Easaw, JC; Grinshtein, N; Hao, X; Kaplan, DR; King, JC; Luchman, A; Lun, X; Robbins, SM; Senger, DL; Uehling, D; Wang, X; Weiss, S; Wells, JC; Wrana, JL, 2016) |
| " More generally, these results suggest that traditional therapy in combination with local, as opposed to systemic, delivery of angiogenesis inhibitors may be able to increase median survival for patients with glioblastoma." | 1.40 | Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma. ( Bow, H; Brem, H; Hwang, LS; Murray, L; Salditch, Q; Schildhaus, N; Tyler, B; Weingart, J; Xing, J; Ye, X; Zhang, Y, 2014) |
| "Temozolomide (TMZ) is a first-line chemotherapeutic agent but the efficacy is limited by intrinsic and acquired resistance in GBM." | 1.40 | Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells. ( Chen, YS; Chen, ZP; Guan, S; Guo, CC; Li, WP; Li, WY; Mou, YG; Sai, K; Wang, J; Yang, QY, 2014) |
| "We developed a mouse model of Lynch syndrome (Lgr5-CreERT2;Msh2(flox/-) mice) and found that environmental factors can modify the number and mutability of the MMR-deficient stem cells." | 1.40 | Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome. ( Cantelli, E; De Vries, S; Dekker, M; Delzenne-Goette, E; Plug, M; Song, JY; Te Riele, H; Van Der Wal, A; Van Gerwen, B; Wojciechowicz, K, 2014) |
| "Temozolomide (TMZ) is an alkylating agent shown to prolong survival in patients with high grade glioma and is routinely used to treat melanoma brain metastases." | 1.39 | Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. ( Archer, GE; Bigner, DD; Choi, BD; Cui, X; Flores, C; Herndon, JE; Johnson, LA; Mitchell, DA; Sampson, JH; Sanchez-Perez, LA; Schmittling, RJ; Snyder, D, 2013) |
| "Glioblastoma is the most lethal brain cancer." | 1.39 | Antitumor activity of (2E,5Z)-5-(2-hydroxybenzylidene)-2-((4-phenoxyphenyl)imino) thiazolidin-4-one, a novel microtubule-depolymerizing agent, in U87MG human glioblastoma cells and corresponding mouse xenograft model. ( Li, C; Li, X; Liu, X; Yan, B; Zhang, Q; Zhou, H, 2013) |
| "Previously, it has been shown that treatment of glioma cells with temozolomide (TMZ) and radiation (XRT) induces the expression of metalloproteinase 14 (MMP14)." | 1.39 | Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas. ( Auffinger, B; Baryshnikov, AY; Borovjagin, A; Dey, M; Guo, D; Han, Y; Kim, CK; Lesniak, MS; Pytel, P; Sarvaiya, P; Thaci, B; Ulasov, I; Yi, R; Zhang, L, 2013) |
| "Glioblastoma multiforme is the most common primary malignant brain tumour, with a median survival of about one year." | 1.38 | A restricted cell population propagates glioblastoma growth after chemotherapy. ( Burns, DK; Chen, J; Kernie, SG; Li, Y; McKay, RM; Parada, LF; Yu, TS, 2012) |
| "Malignant gliomas are highly lethal tumors resistant to current therapies." | 1.37 | Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. ( Barnes, JW; Chaponis, D; Dellagatta, JL; Fast, E; Greene, ER; Kesari, S; Kieran, MW; Kung, AL; Panagrahy, D; Ramakrishna, N; Sauvageot, C; Stiles, C; Wen, PY, 2011) |
| "Oral temozolomide (TMZ) was administered in combination with mFc-endostatin to determine if there was a beneficial synergistic effect." | 1.37 | Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin. ( Brem, H; Grossman, R; Hwang, L; Javaherian, K; Lal, B; Tyler, B; Zadnik, P, 2011) |
| "Thus, we describe a malignant meningioma model system that will be useful for investigating the biology of meningiomas and for preclinical assessment of therapeutic agents." | 1.35 | An orthotopic skull base model of malignant meningioma. ( Baia, GS; Dinca, EB; James, CD; Kimura, ET; Lal, A; McDermott, MW; Ozawa, T; VandenBerg, SR, 2008) |
| "Glioblastomas are highly aggressive primary brain tumors." | 1.35 | Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. ( Claes, A; Heerschap, A; Jeuken, J; Leenders, WP; Maass, C; Wesseling, P, 2008) |
| "After detection of an optic glioma by manganese-enhanced magnetic resonance imaging, we randomized mice to either treatment or control groups." | 1.35 | Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. ( Banerjee, D; Garbow, JR; Gutmann, DH; Hegedus, B; Perry, A; Rothermich, S; Rubin, JB; Yeh, TH, 2008) |
| "Indeed melanomas have proven resistant to apoptosis (type I programmed cell death (PCD)) and consequently to most chemotherapy and immunotherapy." | 1.34 | Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. ( De Neve, N; Gras, T; Kiss, R; Le Mercier, M; Lefranc, F; Mathieu, V; Roland, I; Sauvage, S, 2007) |
| "Temozolomide treatment of high-grade tv-a gliomas provided a 14-day growth delay compared with vehicle controls." | 1.34 | Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma. ( Hambardzumyan, D; Holland, EC; Kreger, AR; Leopold, WR; McConville, P; Moody, JB; Rehemtulla, A; Ross, BD; Woolliscroft, MJ, 2007) |
| " Pharmacokinetics studies revealed that GPI 15427 possesses a substantial oral bioavailability (plasma Cmax after a single dose of 40 mg/kg: 1041+/-516 ng/ml)." | 1.33 | Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. ( Alemu, C; Calvin, D; Graziani, G; Hoover, R; Lapidus, R; Leonetti, C; Morgan, L; Scarsella, M; Tang, Z; Tentori, L; Vergati, M; Woznizk, K; Xu, W; Zhang, J, 2005) |
| "Gliomas are primary brain tumors associated with a poor prognosis partly due to resistance to conventional therapies." | 1.33 | Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model. ( Itasaka, S; Kim, JT; Lee, JI; Nam, DH, 2006) |
| "Tamoxifen and hypericin were able to greatly increase the growth-inhibitory and apoptosis-stimulatory potency of temozolomide via the downregulation of critical cell cycle-regulatory and prosurvival components." | 1.33 | Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin. ( Chen, TC; Gupta, V; Hofman, FM; Kardosh, A; Liebes, LF; Schönthal, AH; Su, YS; Wang, W, 2006) |
| " In contrast, the cytotoxic drug temozolomide, when used in combination with HIF-1alpha knockdown, exhibited a superadditive and likely synergistic therapeutic effect compared with the monotherapy of either treatment alone in the D54MG glioma model." | 1.33 | Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. ( Albert, DH; Fesik, SW; Li, L; Lin, X; Shen, Y; Shoemaker, AR, 2006) |
| " It is proposed that the net balance of antiangiogenic drug-mediated pharmacodynamic actions will determine how drug disposition in tumors may be affected." | 1.32 | Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. ( Gallo, JM; Guo, P; Li, S; Ma, J; Reed, K, 2003) |
| "Temozolomide (TMZ) is a chemotherapeutic agent used in the treatment of high-grade brain tumors." | 1.32 | Formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with temozolomide: implications for the treatment of low-grade adult and pediatric brain tumors. ( Berger, MS; Bodell, WJ; Gaikwad, NW; Miller, D, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 26 (17.57) | 29.6817 |
| 2010's | 97 (65.54) | 24.3611 |
| 2020's | 25 (16.89) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 3 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Wang, Y | 6 |
| Wang, X | 10 |
| Wu, D | 4 |
| Qi, J | 3 |
| Zhang, Y | 10 |
| Wang, K | 1 |
| Zhou, D | 1 |
| Meng, QM | 1 |
| Nie, E | 1 |
| Wang, Q | 3 |
| Yu, RT | 1 |
| Zhou, XP | 1 |
| Urbantat, RM | 1 |
| Jelgersma, C | 1 |
| Brandenburg, S | 1 |
| Nieminen-Kelhä, M | 1 |
| Kremenetskaia, I | 1 |
| Zollfrank, J | 1 |
| Mueller, S | 1 |
| Rubarth, K | 1 |
| Koch, A | 1 |
| Vajkoczy, P | 1 |
| Acker, G | 1 |
| Vengoji, R | 1 |
| Atri, P | 1 |
| Macha, MA | 1 |
| Seshacharyulu, P | 1 |
| Perumal, N | 1 |
| Mallya, K | 1 |
| Liu, Y | 7 |
| Smith, LM | 1 |
| Rachagani, S | 1 |
| Mahapatra, S | 1 |
| Ponnusamy, MP | 1 |
| Jain, M | 1 |
| Batra, SK | 1 |
| Shonka, N | 1 |
| Campian, JL | 1 |
| Ghosh, S | 1 |
| Kapoor, V | 1 |
| Yan, R | 1 |
| Thotala, S | 1 |
| Jash, A | 1 |
| Hu, T | 1 |
| Mahadevan, A | 1 |
| Rifai, K | 1 |
| Page, L | 1 |
| Lee, BH | 1 |
| Ferrando-Martinez, S | 1 |
| Wolfarth, AA | 1 |
| Yang, SH | 1 |
| Hallahan, D | 1 |
| Chheda, MG | 1 |
| Thotala, D | 1 |
| Charbonneau, M | 1 |
| Harper, K | 1 |
| Brochu-Gaudreau, K | 1 |
| Perreault, A | 1 |
| Roy, LO | 1 |
| Lucien, F | 1 |
| Tian, S | 1 |
| Fortin, D | 1 |
| Dubois, CM | 1 |
| Li, T | 1 |
| Fu, X | 1 |
| Wang, J | 9 |
| Shang, W | 1 |
| Zhang, L | 7 |
| Li, J | 13 |
| Dong, W | 2 |
| Fekete, A | 1 |
| Chen, X | 4 |
| Liu, H | 2 |
| Beilhartz, GL | 1 |
| Bahrampour, S | 1 |
| Xiong, Y | 1 |
| Yang, Q | 1 |
| Zhao, H | 4 |
| Kong, T | 1 |
| Morioka, MS | 1 |
| Jung, G | 1 |
| Kim, JE | 1 |
| Schramek, D | 1 |
| Dirks, PB | 2 |
| Song, Y | 2 |
| Kim, TH | 1 |
| He, Y | 2 |
| Wanggou, S | 1 |
| Li, X | 12 |
| Melnyk, RA | 1 |
| Wang, LY | 2 |
| Huang, X | 1 |
| Tan, MSY | 1 |
| Sandanaraj, E | 1 |
| Chong, YK | 1 |
| Lim, SW | 1 |
| Koh, LWH | 1 |
| Ng, WH | 1 |
| Tan, NS | 1 |
| Tan, P | 1 |
| Ang, BT | 2 |
| Tang, C | 2 |
| Cameron, BD | 1 |
| Traver, G | 1 |
| Roland, JT | 1 |
| Brockman, AA | 1 |
| Dean, D | 1 |
| Johnson, L | 1 |
| Boyd, K | 2 |
| Ihrie, RA | 1 |
| Freeman, ML | 1 |
| Adilijiang, A | 1 |
| Hirano, M | 1 |
| Okuno, Y | 1 |
| Aoki, K | 1 |
| Ohka, F | 1 |
| Maeda, S | 1 |
| Tanahashi, K | 1 |
| Motomura, K | 1 |
| Shimizu, H | 1 |
| Yamaguchi, J | 1 |
| Wakabayashi, T | 1 |
| Natsume, A | 1 |
| Çetin, A | 1 |
| Biltekin, B | 1 |
| Enríquez Pérez, J | 1 |
| Kopecky, J | 1 |
| Visse, E | 1 |
| Darabi, A | 1 |
| Siesjö, P | 1 |
| Lomeli, N | 1 |
| Di, K | 1 |
| Pearre, DC | 1 |
| Chung, TF | 1 |
| Bota, DA | 1 |
| Ning, J | 2 |
| Wakimoto, H | 1 |
| von Roemeling, CA | 1 |
| Qie, Y | 1 |
| Yuan, H | 1 |
| Liu, X | 7 |
| Yang, Z | 1 |
| Yang, M | 1 |
| Deng, W | 1 |
| Bruno, KA | 1 |
| Chan, CK | 1 |
| Lee, AS | 1 |
| Rosenfeld, SS | 1 |
| Yun, K | 1 |
| Johnson, AJ | 1 |
| Mitchell, DA | 2 |
| Jiang, W | 1 |
| Kim, BYS | 1 |
| van Erp, AEM | 1 |
| van Houdt, L | 1 |
| Hillebrandt-Roeffen, MHS | 1 |
| van Bree, NFHN | 1 |
| Flucke, UE | 1 |
| Mentzel, T | 1 |
| Shipley, J | 1 |
| Desar, IME | 1 |
| Fleuren, EDG | 1 |
| Versleijen-Jonkers, YMH | 1 |
| van der Graaf, WTA | 1 |
| Zhang, Z | 2 |
| Chen, Y | 4 |
| Chen, H | 2 |
| Yang, Y | 2 |
| Li, C | 3 |
| Zhan, W | 1 |
| Tan, Q | 1 |
| Xie, C | 1 |
| Sharma, HS | 1 |
| Sharma, A | 1 |
| Li, PC | 1 |
| Chen, SY | 1 |
| Xiangfei, D | 1 |
| Mao, C | 1 |
| Wu, CH | 1 |
| Shih, JC | 1 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Li, H | 6 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 3 |
| Song, J | 3 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 2 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Zhang, S | 2 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Sun, Y | 2 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Zhang, D | 2 |
| Huang, W | 1 |
| Cui, Y | 2 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xu, C | 2 |
| Xiang, Y | 1 |
| Xu, X | 1 |
| Zhou, L | 3 |
| Dong, X | 1 |
| Tang, S | 1 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tang, X | 1 |
| Tao, F | 1 |
| Xiang, W | 2 |
| Zhao, Y | 2 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Huang, Y | 2 |
| Chen, L | 5 |
| Shan, A | 1 |
| Wu, M | 2 |
| Ma, Q | 2 |
| Zhang, E | 1 |
| Zhang, J | 8 |
| Li, Y | 8 |
| Xue, F | 1 |
| Deng, L | 1 |
| Liu, L | 2 |
| Yan, Z | 2 |
| Meng, J | 1 |
| Chen, G | 2 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Ren, Y | 1 |
| Li, P | 1 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, F | 2 |
| Wang, YS | 1 |
| Wang, C | 3 |
| Zhou, X | 2 |
| Wang, W | 5 |
| Wang, S | 3 |
| Hou, J | 2 |
| Zhang, A | 1 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Wang, L | 3 |
| Zhu, J | 2 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Zhao, Z | 1 |
| Qu, Y | 2 |
| Yao, H | 1 |
| Lee, DF | 1 |
| Shen, J | 3 |
| Wen, L | 1 |
| Huang, G | 2 |
| Xie, X | 1 |
| Zhao, Q | 1 |
| Hu, W | 1 |
| Wu, X | 1 |
| Lu, J | 3 |
| Li, M | 1 |
| Wu, W | 1 |
| Du, F | 1 |
| Ji, H | 1 |
| Yang, X | 3 |
| Xu, Z | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Huang, H | 1 |
| Wei, Y | 2 |
| Gao, Y | 2 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 2 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 2 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 1 |
| Kong, X | 1 |
| Li, S | 3 |
| Zhang, M | 4 |
| Zhang, H | 2 |
| Yang, T | 2 |
| Dong, Y | 1 |
| Xu, Y | 1 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Zheng, Y | 2 |
| Luo, Z | 1 |
| Mei, Z | 1 |
| Yao, Y | 1 |
| Liu, Z | 2 |
| Liang, C | 1 |
| Yang, H | 1 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Huang, Z | 1 |
| Qian, J | 1 |
| Ge, J | 1 |
| Hu, J | 2 |
| Wang, H | 7 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Yan, W | 1 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Zhang, T | 2 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 1 |
| Mu, W | 1 |
| Liu, C | 3 |
| Gao, F | 2 |
| Qi, Y | 1 |
| Lu, H | 1 |
| Zhang, X | 6 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Shi, Y | 4 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 2 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Liu, Q | 1 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Chen, S | 2 |
| Fu, D | 1 |
| Li, Z | 2 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Lu, Y | 3 |
| Xi, J | 1 |
| Chen, W | 2 |
| Hu, X | 1 |
| Zhang, F | 1 |
| Wei, H | 1 |
| Wang, Z | 1 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Zhang, Q | 4 |
| Lyu, Y | 1 |
| Huang, J | 1 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Brown, D | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 1 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Fan, Y | 2 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 1 |
| Guan, H | 1 |
| Li, D | 2 |
| Tan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Das, S | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Ma, Y | 2 |
| Gao, W | 1 |
| Ma, S | 1 |
| Lin, W | 2 |
| Zhou, T | 1 |
| Wu, T | 1 |
| Wu, Q | 1 |
| Ye, C | 1 |
| He, X | 1 |
| Jiang, F | 1 |
| Yuan, D | 1 |
| Chen, Q | 1 |
| Hong, M | 1 |
| Chen, K | 1 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Zhao, J | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jiang, J | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Song, H | 3 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 1 |
| Zhang, YY | 1 |
| Zhu, Y | 2 |
| Lu, DZ | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 1 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Jiang, X | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| He, Z | 1 |
| Chen, B | 2 |
| Wu, J | 4 |
| Du, X | 1 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 1 |
| Sun, J | 1 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 2 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Jiang, Y | 2 |
| Feng, H | 1 |
| Chang, Y | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Chen, J | 2 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Wu, Y | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| Li, B | 2 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Feng, X | 1 |
| Gao, R | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Wei, L | 1 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Wang, T | 1 |
| Li, Q | 2 |
| Cao, T | 1 |
| Guo, L | 1 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Sun, B | 1 |
| Cao, P | 1 |
| Gu, S | 1 |
| Sun, X | 2 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 2 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Yang, S | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Li, G | 1 |
| Hou, G | 1 |
| Cui, J | 1 |
| Xie, H | 1 |
| Sun, Z | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| Han, C | 1 |
| White, K | 1 |
| Park, HJ | 1 |
| Ding, D | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Feng, J | 2 |
| Qian, Y | 1 |
| Cheng, Q | 1 |
| Ma, H | 1 |
| Ren, X | 1 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Guo, J | 1 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Liao, W | 1 |
| Zhang, P | 1 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Li, F | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Kim, H | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Forrest, WF | 1 |
| Alicke, B | 1 |
| Mayba, O | 1 |
| Osinska, M | 1 |
| Jakubczak, M | 1 |
| Piatkowski, P | 1 |
| Choniawko, L | 1 |
| Starr, A | 1 |
| Gould, SE | 1 |
| DuRoss, AN | 1 |
| Landry, MR | 1 |
| Thomas, CR | 1 |
| Neufeld, MJ | 1 |
| Sun, C | 1 |
| Shi, L | 1 |
| Gu, J | 1 |
| Song, C | 1 |
| Zhou, Q | 1 |
| Qi, S | 2 |
| Vaidya, KS | 1 |
| Mitten, MJ | 1 |
| Zelaya-Lazo, AL | 1 |
| Oleksijew, A | 1 |
| Alvey, C | 1 |
| Falls, HD | 1 |
| Mishra, S | 1 |
| Palma, J | 3 |
| Ansell, P | 1 |
| Phillips, AC | 1 |
| Reilly, EB | 1 |
| Anderson, M | 1 |
| Boghaert, ER | 1 |
| Randles, A | 1 |
| Wirsching, HG | 1 |
| Dean, JA | 1 |
| Cheng, YK | 1 |
| Emerson, S | 1 |
| Pattwell, SS | 1 |
| Holland, EC | 3 |
| Michor, F | 1 |
| Li, XC | 1 |
| Wu, BS | 1 |
| Wang, ZF | 1 |
| Ma, C | 1 |
| Li, YR | 1 |
| Yao, J | 1 |
| Jin, XQ | 1 |
| Li, ZQ | 1 |
| Babu, D | 1 |
| Mudiraj, A | 1 |
| Yadav, N | 1 |
| Y B V K, C | 1 |
| Panigrahi, M | 1 |
| Prakash Babu, P | 1 |
| Pinheiro, L | 1 |
| Perdomo-Pantoja, A | 1 |
| Casaos, J | 1 |
| Huq, S | 1 |
| Paldor, I | 1 |
| Vigilar, V | 1 |
| Mangraviti, A | 2 |
| Witham, TF | 1 |
| Brem, H | 7 |
| Tyler, B | 4 |
| Smit, AM | 1 |
| Kilian, S | 1 |
| Emsley, RA | 1 |
| Luckhoff, HK | 1 |
| Swartz, L | 1 |
| Seedat, S | 1 |
| Asmal, L | 1 |
| Kloppers, JF | 1 |
| de Kock, A | 1 |
| Cronjé, J | 1 |
| van Marle, AC | 1 |
| Aouad, MR | 1 |
| Khan, DJO | 1 |
| Said, MA | 1 |
| Al-Kaff, NS | 1 |
| Rezki, N | 1 |
| Ali, AA | 1 |
| Bouqellah, N | 1 |
| Hagar, M | 1 |
| Sanga, G | 1 |
| Jao, I | 1 |
| Mumba, N | 1 |
| Mwalukore, S | 1 |
| Kamuya, D | 1 |
| Davies, A | 1 |
| McGready, R | 1 |
| Rijken, MJ | 1 |
| Turner, C | 1 |
| Than, HH | 1 |
| Tun, NW | 1 |
| Min, AM | 1 |
| Hla, S | 1 |
| Wai, NS | 1 |
| Proux, K | 1 |
| Min, TH | 1 |
| Gilder, ME | 1 |
| Sneddon, A | 1 |
| Sorbera, M | 1 |
| Fischetti, B | 1 |
| Khaimova, R | 1 |
| Niewinski, M | 1 |
| Wen, K | 1 |
| Tarke, A | 1 |
| Sidney, J | 1 |
| Methot, N | 1 |
| Yu, ED | 1 |
| Dan, JM | 1 |
| Goodwin, B | 1 |
| Rubiro, P | 1 |
| Sutherland, A | 1 |
| Wang, E | 1 |
| Frazier, A | 1 |
| Ramirez, SI | 1 |
| Rawlings, SA | 1 |
| Smith, DM | 1 |
| da Silva Antunes, R | 1 |
| Peters, B | 1 |
| Scheuermann, RH | 1 |
| Weiskopf, D | 1 |
| Crotty, S | 1 |
| Grifoni, A | 1 |
| Sette, A | 1 |
| Yan, P | 1 |
| Liang, DY | 1 |
| Xu, WH | 1 |
| Xue, L | 1 |
| Yu, MF | 1 |
| Shen, JH | 1 |
| Liu, QH | 1 |
| Peng, YB | 1 |
| Arenas, M | 1 |
| Algara, M | 1 |
| De Febrer, G | 1 |
| Rubio, C | 1 |
| Sanz, X | 1 |
| de la Casa, MA | 1 |
| Vasco, C | 1 |
| Marín, J | 1 |
| Fernández-Letón, P | 1 |
| Villar, J | 1 |
| Torres-Royo, L | 1 |
| Villares, P | 1 |
| Membrive, I | 1 |
| Acosta, J | 1 |
| López-Cano, M | 1 |
| Araguas, P | 1 |
| Quera, J | 1 |
| Rodríguez-Tomás, F | 1 |
| Montero, A | 1 |
| Buchler, A | 1 |
| Munch, M | 1 |
| Farber, G | 1 |
| Zhao, X | 1 |
| Al-Haddad, R | 1 |
| Farber, E | 1 |
| Rotstein, BH | 1 |
| Long, T | 1 |
| Yang, N | 1 |
| Zeng, S | 1 |
| Zheng, K | 1 |
| Liao, G | 1 |
| Hu, S | 1 |
| De Gregori, S | 1 |
| De Silvestri, A | 1 |
| Molinaro, MD | 1 |
| Monzillo, V | 1 |
| Biscarini, S | 1 |
| Colaneri, M | 1 |
| Gallazzi, I | 1 |
| Bartoli, A | 1 |
| Bruno, R | 1 |
| Seminari, E | 1 |
| Dang, W | 1 |
| Xiao, J | 2 |
| Miao, J | 1 |
| Cao, M | 1 |
| Yao, X | 1 |
| Yu, S | 1 |
| Bian, X | 1 |
| Norlin, JM | 1 |
| Kellerborg, K | 1 |
| Odin, P | 1 |
| Azzalin, A | 1 |
| Nato, G | 1 |
| Parmigiani, E | 1 |
| Garello, F | 1 |
| Buffo, A | 1 |
| Magrassi, L | 1 |
| Velpula, KK | 1 |
| Guda, MR | 1 |
| Sahu, K | 1 |
| Tuszynski, J | 1 |
| Asuthkar, S | 1 |
| Bach, SE | 1 |
| Lathia, JD | 1 |
| Tsung, AJ | 1 |
| Xu, B | 1 |
| Ye, MH | 1 |
| Lv, SG | 1 |
| Wang, QX | 1 |
| Wu, MJ | 1 |
| Xiao, B | 1 |
| Kang, CS | 1 |
| Zhu, XG | 1 |
| Egeland, M | 1 |
| Guinaudie, C | 1 |
| Du Preez, A | 1 |
| Musaelyan, K | 1 |
| Zunszain, PA | 1 |
| Fernandes, C | 1 |
| Pariante, CM | 1 |
| Thuret, S | 1 |
| Welker, AM | 2 |
| Jaros, BD | 1 |
| An, M | 1 |
| Beattie, CE | 2 |
| Peng, P | 1 |
| Wei, W | 1 |
| Long, C | 1 |
| Mohanty, S | 1 |
| Chen, Z | 3 |
| Li, K | 1 |
| Morais, GR | 1 |
| Klockow, J | 1 |
| Yerneni, K | 1 |
| Pisani, L | 1 |
| Chin, FT | 1 |
| Mitra, S | 1 |
| Cheshier, S | 1 |
| Chang, E | 1 |
| Gambhir, SS | 1 |
| Rao, J | 1 |
| Loadman, PM | 1 |
| Falconer, RA | 1 |
| Daldrup-Link, HE | 1 |
| Canella, A | 1 |
| Yoo, JY | 2 |
| Xu, J | 1 |
| Abas, FS | 1 |
| Kesanakurti, D | 1 |
| Nagarajan, P | 1 |
| Sulman, EP | 1 |
| Liu, J | 1 |
| Gumin, J | 1 |
| Lang, FF | 1 |
| Gurcan, MN | 1 |
| Kaur, B | 2 |
| Sampath, D | 1 |
| Puduvalli, VK | 1 |
| Azambuja, JH | 1 |
| da Silveira, EF | 1 |
| de Carvalho, TR | 1 |
| Oliveira, PS | 1 |
| Pacheco, S | 1 |
| do Couto, CT | 1 |
| Beira, FT | 1 |
| Stefanello, FM | 1 |
| Spanevello, RM | 1 |
| Braganhol, E | 1 |
| Burri, SH | 1 |
| Gondi, V | 1 |
| Brown, PD | 1 |
| Mehta, MP | 1 |
| Herting, CJ | 1 |
| Pitter, KL | 1 |
| Szulzewsky, F | 1 |
| Kaffes, I | 1 |
| Kaluzova, M | 1 |
| Park, JC | 1 |
| Cimino, PJ | 1 |
| Brennan, C | 1 |
| Wang, B | 1 |
| Hambardzumyan, D | 2 |
| Adhikari, B | 1 |
| Brandel, MG | 1 |
| Futalan, D | 1 |
| Akers, J | 1 |
| Deming, T | 1 |
| Chen, CC | 1 |
| Carter, BS | 1 |
| Mathivet, T | 1 |
| Bouleti, C | 1 |
| Van Woensel, M | 1 |
| Stanchi, F | 1 |
| Verschuere, T | 1 |
| Phng, LK | 1 |
| Dejaegher, J | 1 |
| Balcer, M | 1 |
| Matsumoto, K | 1 |
| Georgieva, PB | 1 |
| Belmans, J | 1 |
| Sciot, R | 1 |
| Stockmann, C | 1 |
| Mazzone, M | 1 |
| De Vleeschouwer, S | 1 |
| Gerhardt, H | 1 |
| Marques-Torrejon, MA | 1 |
| Gangoso, E | 1 |
| Pollard, SM | 1 |
| Su, YT | 1 |
| Chen, R | 1 |
| Chen, LY | 1 |
| Lappin, H | 1 |
| Vasconcelos, G | 1 |
| Lita, A | 1 |
| Maric, D | 1 |
| Li, A | 1 |
| Celiku, O | 1 |
| Zhang, W | 2 |
| Meetze, K | 1 |
| Estok, T | 1 |
| Larion, M | 1 |
| Abu-Asab, M | 1 |
| Zhuang, Z | 2 |
| Yang, C | 1 |
| Gilbert, MR | 2 |
| Clemente, N | 1 |
| Ferrara, B | 1 |
| Gigliotti, CL | 1 |
| Boggio, E | 1 |
| Capucchio, MT | 1 |
| Biasibetti, E | 1 |
| Schiffer, D | 1 |
| Mellai, M | 1 |
| Annovazzi, L | 1 |
| Cangemi, L | 1 |
| Muntoni, E | 1 |
| Miglio, G | 1 |
| Dianzani, U | 1 |
| Battaglia, L | 1 |
| Dianzani, C | 1 |
| Cai, T | 1 |
| Pawlowska, E | 1 |
| Szczepanska, J | 1 |
| Szatkowska, M | 1 |
| Blasiak, J | 1 |
| Salazar, N | 1 |
| Carlson, JC | 1 |
| Huang, K | 1 |
| Oderup, C | 1 |
| Gross, J | 1 |
| Jang, AD | 1 |
| Burke, TM | 1 |
| Lewén, S | 1 |
| Scholz, A | 1 |
| Huang, S | 1 |
| Nease, L | 1 |
| Kosek, J | 1 |
| Mittelbronn, M | 2 |
| Butcher, EC | 1 |
| Tu, H | 1 |
| Zabel, BA | 1 |
| Dai, B | 1 |
| Qi, N | 1 |
| Zhang, G | 1 |
| Choi, C | 1 |
| Kim, HM | 1 |
| Shon, J | 1 |
| Park, J | 1 |
| Kim, HT | 1 |
| Kang, SH | 1 |
| Oh, SH | 1 |
| Kim, NK | 1 |
| Kim, OJ | 1 |
| Ji, M | 1 |
| Lü, YH | 1 |
| Lai, FF | 1 |
| Chen, XG | 1 |
| Provost, C | 1 |
| Rozenblum-Beddok, L | 1 |
| Nataf, V | 1 |
| Merabtene, F | 1 |
| Prignon, A | 1 |
| Talbot, JN | 1 |
| Yang, L | 1 |
| Zou, L | 1 |
| Kawaguchi, K | 1 |
| Higuchi, T | 1 |
| Han, Q | 1 |
| Tan, Y | 1 |
| Igarashi, K | 1 |
| Zhao, M | 1 |
| Miyake, K | 1 |
| Kiyuna, T | 1 |
| Miyake, M | 1 |
| Ohshiro, H | 1 |
| Sugisawa, N | 1 |
| Razmjooei, S | 1 |
| Wangsiricharoen, S | 1 |
| Chmielowski, B | 1 |
| Nelson, SD | 1 |
| Russell, TA | 1 |
| Dry, SM | 1 |
| Eckardt, MA | 1 |
| Singh, AS | 1 |
| Singh, SR | 1 |
| Eilber, FC | 1 |
| Unno, M | 1 |
| Hoffman, RM | 1 |
| Guan, X | 1 |
| Hasan, MN | 1 |
| Begum, G | 1 |
| Kohanbash, G | 1 |
| Carney, KE | 1 |
| Pigott, VM | 1 |
| Persson, AI | 1 |
| Castro, MG | 2 |
| Jia, W | 1 |
| Hribar, KC | 1 |
| Wheeler, CJ | 1 |
| Bazarov, A | 1 |
| Varshneya, K | 1 |
| Yamada, R | 1 |
| Buckley, P | 1 |
| Patil, CG | 1 |
| Pandey, V | 1 |
| Ranjan, N | 1 |
| Narne, P | 1 |
| Babu, PP | 1 |
| Wei, KC | 1 |
| Chu, PC | 1 |
| Wang, HY | 1 |
| Huang, CY | 1 |
| Chen, PY | 1 |
| Tsai, HC | 1 |
| Lu, YJ | 1 |
| Lee, PY | 1 |
| Tseng, IC | 1 |
| Feng, LY | 1 |
| Hsu, PW | 1 |
| Yen, TC | 1 |
| Liu, HL | 1 |
| Sanchez-Perez, LA | 1 |
| Choi, BD | 1 |
| Archer, GE | 1 |
| Cui, X | 1 |
| Flores, C | 1 |
| Johnson, LA | 1 |
| Schmittling, RJ | 1 |
| Snyder, D | 1 |
| Herndon, JE | 1 |
| Bigner, DD | 3 |
| Sampson, JH | 1 |
| Zhou, H | 1 |
| Yan, B | 1 |
| Epple, LM | 1 |
| Dodd, RD | 1 |
| Merz, AL | 1 |
| Dechkovskaia, AM | 1 |
| Herring, M | 1 |
| Winston, BA | 1 |
| Lencioni, AM | 1 |
| Russell, RL | 1 |
| Madsen, H | 1 |
| Nega, M | 1 |
| Dusto, NL | 1 |
| White, J | 1 |
| Nicchitta, CV | 1 |
| Serkova, NJ | 1 |
| Graner, MW | 1 |
| Mantwill, K | 1 |
| Naumann, U | 1 |
| Seznec, J | 1 |
| Girbinger, V | 1 |
| Lage, H | 1 |
| Surowiak, P | 1 |
| Beier, D | 1 |
| Schlegel, J | 1 |
| Holm, PS | 1 |
| Li, R | 1 |
| Tang, D | 1 |
| Dong, J | 1 |
| Ulasov, I | 1 |
| Thaci, B | 1 |
| Sarvaiya, P | 1 |
| Yi, R | 1 |
| Guo, D | 1 |
| Auffinger, B | 1 |
| Pytel, P | 1 |
| Kim, CK | 4 |
| Borovjagin, A | 1 |
| Dey, M | 2 |
| Han, Y | 2 |
| Baryshnikov, AY | 1 |
| Lesniak, MS | 2 |
| Leshchenko, VV | 1 |
| Kuo, PY | 1 |
| Jiang, Z | 1 |
| Thirukonda, VK | 1 |
| Parekh, S | 1 |
| Grossman, R | 3 |
| Brastianos, H | 1 |
| Blakeley, JO | 1 |
| Lal, B | 2 |
| Zadnik, P | 2 |
| Hwang, L | 3 |
| Wicks, RT | 1 |
| Goodwin, RC | 1 |
| Liu, XY | 1 |
| Ren, YJ | 1 |
| Yang, WQ | 1 |
| Ming, ZJ | 1 |
| Yang, JM | 1 |
| Magaña-Maldonado, R | 1 |
| Manoutcharian, K | 1 |
| Hernández-Pedro, NY | 1 |
| Rangel-López, E | 1 |
| Pérez-De la Cruz, V | 1 |
| Rodríguez-Balderas, C | 1 |
| Sotelo, J | 1 |
| Pineda, B | 1 |
| Bow, H | 1 |
| Hwang, LS | 1 |
| Schildhaus, N | 1 |
| Xing, J | 1 |
| Murray, L | 1 |
| Salditch, Q | 1 |
| Ye, X | 1 |
| Weingart, J | 1 |
| Gil del Alcazar, CR | 1 |
| Hardebeck, MC | 1 |
| Mukherjee, B | 1 |
| Tomimatsu, N | 1 |
| Gao, X | 1 |
| Yan, J | 1 |
| Xie, XJ | 1 |
| Bachoo, R | 1 |
| Li, L | 2 |
| Habib, AA | 1 |
| Burma, S | 1 |
| Candolfi, M | 1 |
| Yagiz, K | 1 |
| Wibowo, M | 1 |
| Ahlzadeh, GE | 1 |
| Puntel, M | 1 |
| Ghiasi, H | 1 |
| Kamran, N | 1 |
| Paran, C | 1 |
| Lowenstein, PR | 1 |
| Meco, D | 1 |
| Servidei, T | 1 |
| Lamorte, G | 1 |
| Binda, E | 1 |
| Arena, V | 1 |
| Riccardi, R | 1 |
| Chen, TC | 4 |
| Cho, HY | 2 |
| Barath, M | 1 |
| Sharma, N | 1 |
| Hofman, FM | 4 |
| Schönthal, AH | 4 |
| Wainwright, DA | 1 |
| Chang, AL | 1 |
| Balyasnikova, IV | 1 |
| Tobias, A | 1 |
| Cheng, Y | 1 |
| Kim, JW | 1 |
| Qiao, J | 1 |
| Sai, K | 2 |
| Li, WY | 1 |
| Chen, YS | 1 |
| Guan, S | 1 |
| Yang, QY | 2 |
| Guo, CC | 2 |
| Mou, YG | 1 |
| Li, WP | 1 |
| Chen, ZP | 2 |
| Gatti, L | 1 |
| Sevko, A | 1 |
| De Cesare, M | 1 |
| Arrighetti, N | 1 |
| Manenti, G | 1 |
| Ciusani, E | 1 |
| Verderio, P | 1 |
| Ciniselli, CM | 1 |
| Cominetti, D | 1 |
| Carenini, N | 1 |
| Corna, E | 1 |
| Zaffaroni, N | 1 |
| Rodolfo, M | 1 |
| Rivoltini, L | 1 |
| Umansky, V | 1 |
| Perego, P | 1 |
| Wojciechowicz, K | 1 |
| Cantelli, E | 1 |
| Van Gerwen, B | 1 |
| Plug, M | 1 |
| Van Der Wal, A | 1 |
| Delzenne-Goette, E | 1 |
| Song, JY | 1 |
| De Vries, S | 1 |
| Dekker, M | 1 |
| Te Riele, H | 1 |
| Agnihotri, S | 1 |
| Burrell, K | 1 |
| Buczkowicz, P | 1 |
| Remke, M | 1 |
| Golbourn, B | 1 |
| Chornenkyy, Y | 1 |
| Gajadhar, A | 1 |
| Fernandez, NA | 1 |
| Clarke, ID | 1 |
| Barszczyk, MS | 1 |
| Pajovic, S | 1 |
| Ternamian, C | 1 |
| Head, R | 1 |
| Sabha, N | 1 |
| Sobol, RW | 1 |
| Taylor, MD | 1 |
| Rutka, JT | 1 |
| Jones, C | 1 |
| Zadeh, G | 1 |
| Hawkins, C | 1 |
| Kim, SS | 1 |
| Rait, A | 1 |
| Kim, E | 1 |
| Pirollo, KF | 1 |
| Chang, EH | 1 |
| Lee, SY | 1 |
| Slagle-Webb, B | 1 |
| Rizk, E | 1 |
| Patel, A | 1 |
| Miller, PA | 1 |
| Sung, SS | 1 |
| Connor, JR | 1 |
| Luchman, HA | 1 |
| Stechishin, OD | 1 |
| Nguyen, SA | 1 |
| Lun, XQ | 1 |
| Cairncross, JG | 2 |
| Weiss, S | 2 |
| Nguyen, J | 1 |
| Jhaveri, N | 1 |
| Rosenstein-Sisson, R | 1 |
| Pokorny, JL | 1 |
| Calligaris, D | 1 |
| Iyekegbe, DO | 1 |
| Mueller, D | 1 |
| Bakken, KK | 1 |
| Carlson, BL | 2 |
| Schroeder, MA | 2 |
| Evans, DL | 1 |
| Lou, Z | 1 |
| Decker, PA | 1 |
| Eckel-Passow, JE | 1 |
| Pucci, V | 1 |
| Ma, B | 1 |
| Shumway, SD | 1 |
| Elmquist, WF | 1 |
| Agar, NY | 1 |
| Sarkaria, JN | 3 |
| Miao, W | 1 |
| Lian, S | 1 |
| Guo, G | 1 |
| Deibert, CP | 1 |
| Zussman, BM | 1 |
| Engh, JA | 1 |
| Bryukhovetskiy, I | 1 |
| Bryukhovetsky, A | 1 |
| Khotimchenko, Y | 1 |
| Mischenko, P | 1 |
| Tolok, E | 1 |
| Khotimchenko, R | 1 |
| Towner, RA | 1 |
| Ihnat, M | 1 |
| Saunders, D | 1 |
| Bastian, A | 1 |
| Smith, N | 1 |
| Pavana, RK | 1 |
| Gangjee, A | 1 |
| Ouyang, M | 1 |
| White, EE | 1 |
| Ren, H | 1 |
| Guo, Q | 1 |
| Zhang, I | 1 |
| Gao, H | 1 |
| Yanyan, S | 1 |
| Weng, Y | 1 |
| Da Fonseca, A | 1 |
| Shah, S | 1 |
| Manuel, ER | 1 |
| Vonderfecht, SL | 1 |
| Alizadeh, D | 1 |
| Berlin, JM | 1 |
| Badie, B | 1 |
| Radoul, M | 1 |
| Chaumeil, MM | 1 |
| Eriksson, P | 1 |
| Wang, AS | 1 |
| Phillips, JJ | 1 |
| Ronen, SM | 1 |
| Lemasson, B | 1 |
| Galbán, S | 1 |
| Heist, KA | 1 |
| Tsein, C | 1 |
| Chenevert, TL | 1 |
| Rehemtulla, A | 2 |
| Galbán, CJ | 1 |
| Ross, BD | 2 |
| Lun, X | 1 |
| Wells, JC | 1 |
| Grinshtein, N | 1 |
| King, JC | 1 |
| Hao, X | 1 |
| Dang, NH | 1 |
| Aman, A | 1 |
| Uehling, D | 1 |
| Datti, A | 1 |
| Wrana, JL | 1 |
| Easaw, JC | 1 |
| Luchman, A | 1 |
| Kaplan, DR | 1 |
| Robbins, SM | 1 |
| Senger, DL | 1 |
| Cai, S | 1 |
| Bailey, BJ | 1 |
| Reza Saadatzadeh, M | 1 |
| Ding, J | 1 |
| Tonsing-Carter, E | 1 |
| Georgiadis, TM | 1 |
| Zachary Gunter, T | 1 |
| Long, EC | 1 |
| Minto, RE | 1 |
| Gordon, KR | 1 |
| Sen, SE | 1 |
| Cai, W | 1 |
| Eitel, JA | 1 |
| Waning, DL | 1 |
| Bringman, LR | 1 |
| Wells, CD | 1 |
| Murray, ME | 1 |
| Gelbert, LM | 1 |
| Jones, DR | 1 |
| Cohen-Gadol, AA | 1 |
| Mayo, LD | 1 |
| Shannon, HE | 1 |
| Pollok, KE | 1 |
| Feng, W | 1 |
| He, M | 1 |
| Zhao, L | 1 |
| Lei, B | 1 |
| Toren, A | 1 |
| Pismenyuk, T | 1 |
| Yalon, M | 1 |
| Freedman, S | 1 |
| Simon, AJ | 1 |
| Fisher, T | 1 |
| Moshe, I | 1 |
| Reichardt, JK | 1 |
| Constantini, S | 1 |
| Mardor, Y | 1 |
| Last, D | 1 |
| Guez, D | 1 |
| Daniels, D | 1 |
| Assoulin, M | 1 |
| Mehrian-Shai, R | 1 |
| Cheray, M | 1 |
| Pacaud, R | 1 |
| Nadaradjane, A | 1 |
| Oliver, L | 1 |
| Vallette, FM | 1 |
| Cartron, PF | 1 |
| Li, XM | 1 |
| Yin, AA | 1 |
| Yao, L | 1 |
| Bian, H | 1 |
| Pérez-Domper, P | 1 |
| Palomo, V | 1 |
| Gradari, S | 1 |
| Gil, C | 1 |
| de Ceballos, ML | 1 |
| Martínez, A | 1 |
| Trejo, JL | 1 |
| Miyata, H | 1 |
| Ashizawa, T | 1 |
| Iizuka, A | 1 |
| Kondou, R | 1 |
| Nonomura, C | 1 |
| Sugino, T | 1 |
| Urakami, K | 1 |
| Asai, A | 1 |
| Hayashi, N | 1 |
| Mitsuya, K | 1 |
| Nakasu, Y | 1 |
| Yamaguchi, K | 1 |
| Akiyama, Y | 1 |
| Jaime-Ramirez, AC | 1 |
| Dmitrieva, N | 1 |
| Banasavadi-Siddegowda, Y | 1 |
| Relation, T | 1 |
| Bolyard, C | 1 |
| Wojton, J | 1 |
| Ramachandran, R | 1 |
| Junnuthula, VR | 1 |
| Gowd, GS | 1 |
| Ashokan, A | 1 |
| Thomas, J | 1 |
| Peethambaran, R | 1 |
| Thomas, A | 1 |
| Unni, AK | 1 |
| Panikar, D | 1 |
| Nair, SV | 1 |
| Koyakutty, M | 1 |
| League-Pascual, JC | 1 |
| Lester-McCully, CM | 1 |
| Shandilya, S | 1 |
| Ronner, L | 1 |
| Rodgers, L | 1 |
| Cruz, R | 1 |
| Peer, CJ | 1 |
| Figg, WD | 1 |
| Warren, KE | 1 |
| Feng, HB | 1 |
| Jiang, HR | 1 |
| Mei, X | 1 |
| Zhao, YY | 1 |
| Chen, FR | 1 |
| Zhang, ZP | 1 |
| Sugiyama, S | 1 |
| Yamashita, Y | 1 |
| Kikuchi, T | 1 |
| Sonoda, Y | 1 |
| Kumabe, T | 1 |
| Tominaga, T | 1 |
| Kinders, R | 1 |
| Donawho, C | 2 |
| Ellis, PA | 1 |
| Rodriguez, LE | 2 |
| Colon-Lopez, M | 2 |
| Saltarelli, M | 1 |
| LeBlond, D | 1 |
| Lin, CT | 1 |
| Frost, DJ | 1 |
| Luo, Y | 3 |
| Giranda, VL | 2 |
| Kang, GS | 1 |
| Wang, XD | 1 |
| Mohler, ML | 1 |
| Kirichenko, OV | 1 |
| Patil, R | 1 |
| Orr, WE | 1 |
| Miller, DD | 1 |
| Geisert, EE | 1 |
| Guan, R | 1 |
| Zhu, GD | 1 |
| Johnson, EF | 1 |
| Ghoreishi-Haack, N | 1 |
| Jarvis, K | 1 |
| Hradil, VP | 1 |
| Cox, BF | 1 |
| Klinghofer, V | 1 |
| Penning, T | 1 |
| Rosenberg, SH | 1 |
| Frost, D | 1 |
| Chua, C | 1 |
| Zaiden, N | 1 |
| Chong, KH | 1 |
| See, SJ | 1 |
| Wong, MC | 1 |
| Akbar, U | 1 |
| Jones, T | 1 |
| Winestone, J | 1 |
| Michael, M | 1 |
| Shukla, A | 1 |
| Duntsch, C | 1 |
| Hashizume, R | 2 |
| Ozawa, T | 3 |
| Dinca, EB | 3 |
| Banerjee, A | 2 |
| Prados, MD | 1 |
| James, CD | 4 |
| Gupta, N | 3 |
| de Vries, NA | 1 |
| Beijnen, JH | 1 |
| van Tellingen, O | 1 |
| Kim, TG | 2 |
| Kim, CH | 2 |
| Park, JS | 1 |
| Park, SD | 2 |
| Chung, DS | 1 |
| Hong, YK | 2 |
| Sheehan, J | 1 |
| Cifarelli, CP | 1 |
| Dassoulas, K | 1 |
| Olson, C | 1 |
| Rainey, J | 1 |
| Han, S | 1 |
| Recinos, VR | 2 |
| Tyler, BM | 3 |
| Bekelis, K | 1 |
| Sunshine, SB | 1 |
| Vellimana, A | 1 |
| Li, KW | 2 |
| Toshimitsu, H | 1 |
| Yoshimoto, Y | 1 |
| Augustine, CK | 2 |
| Padussis, JC | 1 |
| Yoo, JS | 1 |
| Angelica Selim, M | 1 |
| Pruitt, SK | 2 |
| Friedman, HS | 3 |
| Ali-Osman, F | 1 |
| Tyler, DS | 3 |
| Zhang, YH | 1 |
| Yue, ZJ | 1 |
| Tang, GS | 1 |
| Liu, JM | 1 |
| Osmond, GW | 1 |
| Zipfel, PA | 1 |
| Padussis, J | 1 |
| Zhu, X | 1 |
| Fujita, M | 1 |
| Snyder, LA | 1 |
| Okada, H | 1 |
| Scott, AW | 1 |
| Masi, BC | 1 |
| Upadhyay, UM | 1 |
| Patta, YR | 1 |
| Basaldella, L | 1 |
| Langer, RS | 1 |
| Cima, MJ | 1 |
| Chaponis, D | 1 |
| Barnes, JW | 1 |
| Dellagatta, JL | 1 |
| Kesari, S | 1 |
| Fast, E | 1 |
| Sauvageot, C | 1 |
| Panagrahy, D | 1 |
| Greene, ER | 1 |
| Ramakrishna, N | 1 |
| Wen, PY | 1 |
| Kung, AL | 1 |
| Stiles, C | 1 |
| Kieran, MW | 1 |
| Golden, EB | 1 |
| Thomas, S | 1 |
| Sivakumar, W | 1 |
| Louie, SG | 1 |
| Martiniova, L | 1 |
| Chiang, J | 1 |
| Bernardo, M | 1 |
| Lonser, R | 1 |
| Pacak, K | 1 |
| Javaherian, K | 1 |
| Aoki, Y | 1 |
| Prados, M | 1 |
| Yoshimura, J | 1 |
| Siu, IM | 1 |
| Thomale, UW | 1 |
| Jallo, GI | 1 |
| Dagıstan, Y | 1 |
| Karaca, I | 1 |
| Bozkurt, ER | 1 |
| Ozar, E | 1 |
| Yagmurlu, K | 1 |
| Toklu, A | 1 |
| Bilir, A | 1 |
| Yu, TS | 1 |
| McKay, RM | 1 |
| Burns, DK | 1 |
| Kernie, SG | 1 |
| Parada, LF | 1 |
| Keir, ST | 1 |
| Reardon, DA | 1 |
| Gray, LA | 1 |
| Vellimana, AK | 1 |
| Fowers, KD | 1 |
| Okonma, S | 1 |
| Eberhart, CG | 1 |
| Hirst, TC | 1 |
| Vesterinen, HM | 1 |
| Sena, ES | 1 |
| Egan, KJ | 1 |
| Macleod, MR | 1 |
| Whittle, IR | 1 |
| Middleton, MR | 1 |
| Thatcher, N | 1 |
| McMurry, TB | 1 |
| McElhinney, RS | 1 |
| Donnelly, DJ | 1 |
| Margison, GP | 1 |
| Ma, J | 1 |
| Reed, K | 1 |
| Guo, P | 1 |
| Gallo, JM | 1 |
| Bodell, WJ | 1 |
| Gaikwad, NW | 1 |
| Miller, D | 1 |
| Berger, MS | 2 |
| Ueno, T | 1 |
| Ko, SH | 1 |
| Grubbs, E | 1 |
| Tentori, L | 1 |
| Leonetti, C | 1 |
| Scarsella, M | 1 |
| Vergati, M | 1 |
| Xu, W | 1 |
| Calvin, D | 1 |
| Morgan, L | 1 |
| Tang, Z | 1 |
| Woznizk, K | 1 |
| Alemu, C | 1 |
| Hoover, R | 1 |
| Lapidus, R | 1 |
| Graziani, G | 1 |
| Mancuso, A | 1 |
| Zhu, A | 1 |
| Beardsley, NJ | 1 |
| Glickson, JD | 1 |
| Wehrli, S | 1 |
| Pickup, S | 1 |
| Lee, JI | 1 |
| Itasaka, S | 1 |
| Kim, JT | 2 |
| Nam, DH | 2 |
| Gupta, V | 1 |
| Su, YS | 1 |
| Kardosh, A | 1 |
| Liebes, LF | 1 |
| Eyüpoglu, IY | 1 |
| Hahnen, E | 1 |
| Tränkle, C | 1 |
| Savaskan, NE | 1 |
| Siebzehnrübl, FA | 1 |
| Buslei, R | 1 |
| Lemke, D | 1 |
| Wick, W | 1 |
| Fahlbusch, R | 1 |
| Blümcke, I | 1 |
| Kim, JS | 1 |
| Ko, KW | 1 |
| Kong, DS | 1 |
| Kang, CM | 1 |
| Kim, MH | 1 |
| Son, MJ | 1 |
| Song, HS | 1 |
| Shin, HJ | 1 |
| Eoh, W | 1 |
| Chakravarti, A | 1 |
| Erkkinen, MG | 1 |
| Nestler, U | 1 |
| Stupp, R | 1 |
| Mehta, M | 1 |
| Aldape, K | 1 |
| Black, PM | 1 |
| Loeffler, JS | 1 |
| Lin, X | 1 |
| Shoemaker, AR | 1 |
| Albert, DH | 1 |
| Fesik, SW | 1 |
| Shen, Y | 1 |
| Park, JA | 1 |
| Sohn, HJ | 1 |
| Mathieu, V | 1 |
| Le Mercier, M | 1 |
| De Neve, N | 1 |
| Sauvage, S | 1 |
| Gras, T | 1 |
| Roland, I | 1 |
| Lefranc, F | 1 |
| Kiss, R | 1 |
| McConville, P | 1 |
| Moody, JB | 1 |
| Leopold, WR | 1 |
| Kreger, AR | 1 |
| Woolliscroft, MJ | 1 |
| Voicu, R | 1 |
| Baia, GS | 1 |
| Kimura, ET | 1 |
| McDermott, MW | 1 |
| VandenBerg, SR | 1 |
| Lal, A | 1 |
| Claes, A | 1 |
| Jeuken, J | 1 |
| Maass, C | 1 |
| Heerschap, A | 1 |
| Leenders, WP | 1 |
| Hegedus, B | 1 |
| Banerjee, D | 1 |
| Yeh, TH | 1 |
| Rothermich, S | 1 |
| Perry, A | 1 |
| Rubin, JB | 1 |
| Garbow, JR | 1 |
| Gutmann, DH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide[NCT03687957] | Phase 1/Phase 2 | 70 participants (Anticipated) | Interventional | 2019-01-04 | Recruiting | ||
| Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)[NCT05120284] | Phase 2 | 40 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| A FIH Feasibility Study to Evaluate the Safety of Transient Disruption of Blood-brain Barrier in Recurrent Glioblastoma Multiforme (GBM) Patients Using NaviFUS System[NCT03626896] | 6 participants (Actual) | Interventional | 2018-08-17 | Completed | |||
| Phase II Trial of Pemetrexed and Temozolomide in Treating Patients With Relapsed PCNSL[NCT01985451] | Phase 2 | 15 participants (Anticipated) | Interventional | 2013-03-31 | Active, not recruiting | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for temozolomide and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood-Brain Barrier; Bra | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists.
Topics: Animals; Brain Neoplasms; Cause of Death; Chemoradiotherapy; Combined Modality Therapy; Disease Mana | 2018 |
An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme-Role in Pathogenesis and Therapeutic Perspective.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Autophagy; Brain Neoplasms; Cellular Senescen | 2018 |
High-grade glioma mouse models and their applicability for preclinical testing.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biomark | 2009 |
Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Gl | 2013 |
2 trials available for temozolomide and Disease Models, Animal
| Article | Year |
|---|---|
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies | 2021 |
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies | 2021 |
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies | 2021 |
Topics: Adult; Aged; Aged, 80 and over; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies | 2021 |
141 other studies available for temozolomide and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Imipramine impedes glioma progression by inhibiting YAP as a Hippo pathway independent manner and synergizes with temozolomide.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease M | 2021 |
Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2021 |
Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Survival; Computational Biology; | 2021 |
Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models.
Topics: Animals; Brain Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Clinical Trials, Phase I as | 2022 |
The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity/resistance in malignant glial tumors.
Topics: Animals; Brain Neoplasms; Carboplatin; Chick Embryo; Disease Models, Animal; Glioma; Heterografts; H | 2023 |
Mechanism of NURP1 in temozolomide resistance in hypoxia-treated glioma cells via the KDM3A/TFEB axis.
Topics: Animals; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Disease Models, Ani | 2023 |
A designer peptide against the EAG2-Kvβ2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma.
Topics: Animals; Disease Models, Animal; Ether-A-Go-Go Potassium Channels; Glioblastoma; Humans; Mice; Neuro | 2023 |
A STAT3-based gene signature stratifies glioma patients for targeted therapy.
Topics: Animals; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Ge | 2019 |
Bcl2-Expressing Quiescent Type B Neural Stem Cells in the Ventricular-Subventricular Zone Are Resistant to Concurrent Temozolomide/X-Irradiation.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Chemoradiotherapy; Disease Models, Animal; DN | 2019 |
Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Cycle; Cell Survival; Com | 2019 |
Combining Ellagic Acid with Temozolomide Mediates the Cadherin Switch and Angiogenesis in a Glioblastoma Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cell Line, Tumor; Disease Models | 2019 |
Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Cancer Vaccines; Cell Line, Tumor; Combined Modality The | 2020 |
Mitochondrial-associated impairments of temozolomide on neural stem/progenitor cells and hippocampal neurons.
Topics: Animals; Cell Survival; Cells, Cultured; Cytochromes b; Disease Models, Animal; DNA Replication; Hip | 2020 |
Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity.
Topics: Adaptive Immunity; Animals; Antigen Presentation; Apoptosis; CD47 Antigen; Cell Line, Tumor; Cell Pr | 2020 |
Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Child | 2020 |
New advances on the inhibition of Siwei Xiaoliuyin combined with Temozolomide in glioma based on the regulatory mechanism of miRNA21/221.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Models, Animal; Drug Therapy, C | 2020 |
PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2020 |
Generalized Additive Mixed Modeling of Longitudinal Tumor Growth Reduces Bias and Improves Decision Making in Translational Oncology.
Topics: Anilides; Animals; Antineoplastic Agents, Alkylating; Bias; Decision Making; Disease Models, Animal; | 2020 |
Fucoidan-coated nanoparticles target radiation-induced P-selectin to enhance chemoradiotherapy in murine colorectal cancer.
Topics: Animals; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Colorectal Neoplasms; Disease Models, A | 2021 |
[Establishment of a mouse model bearing orthotopic temozolomide-resistant glioma].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2021 |
Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2021 |
Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Models, Animal; Drug Administra | 2021 |
Temozolomide-Induced Changes in Gut Microbial Composition in a Mouse Model of Brain Glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Disease Models, Anima | 2021 |
Rabeprazole has efficacy per se and reduces resistance to temozolomide in glioma via EMT inhibition.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cadherins; Cell Line, Tumor; Disease Mo | 2021 |
Captopril inhibits Matrix Metalloproteinase-2 and extends survival as a temozolomide adjuvant in an intracranial gliosarcoma model.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasm | 2021 |
Inhibitors of GLUT/SLC2A Enhance the Action of BCNU and Temozolomide against High-Grade Gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Biological Transport; Carmustine; Cell Line, Tumor; Cell | 2017 |
Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Antineoplastic Agents, Alkylating; Binding Si | 2017 |
SNORD47, a box C/D snoRNA, suppresses tumorigenesis in glioblastoma.
Topics: Adult; Aged; Animals; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transfor | 2017 |
Depletion of adult neurogenesis using the chemotherapy drug temozolomide in mice induces behavioural and biological changes relevant to depression.
Topics: Animals; Antineoplastic Agents, Alkylating; Behavior, Animal; Biochemical Phenomena; Brain; Brain Ne | 2017 |
Changes in tumor cell heterogeneity after chemotherapy treatment in a xenograft model of glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Glioblastoma; Heter | 2017 |
Atorvastatin augments temozolomide's efficacy in glioblastoma via prenylation-dependent inhibition of Ras signaling.
Topics: Animals; Atorvastatin; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; Disease Mode | 2017 |
A Novel Theranostic Strategy for
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarba | 2017 |
Efficacy of Onalespib, a Long-Acting Second-Generation HSP90 Inhibitor, as a Single Agent and in Combination with Temozolomide against Malignant Gliomas.
Topics: Animals; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Cell Line, Tumor; Cell Movement; Ce | 2017 |
Glioma sensitive or chemoresistant to temozolomide differentially modulate macrophage protumor activities.
Topics: Animals; Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Cell Line, Tumor; Cell Polarity | 2017 |
Genetic driver mutations define the expression signature and microenvironmental composition of high-grade gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cerebral Vent | 2017 |
The use of TMZ embedded hydrogels for the treatment of orthotopic human glioma xenografts.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Anim | 2017 |
Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Alkylating; Blood Vessels; Brain Neoplasms; | 2017 |
Modelling glioblastoma tumour-host cell interactions using adult brain organotypic slice co-culture.
Topics: Aging; Animals; Antigens, CD; Biomarkers, Tumor; Brain; Brain Neoplasms; Cell Communication; Cell Pr | 2018 |
Novel Targeting of Transcription and Metabolism in Glioblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain; Brain Neoplasms; Cell Lin | 2018 |
Solid Lipid Nanoparticles Carrying Temozolomide for Melanoma Treatment. Preliminary In Vitro and In Vivo Studies.
Topics: Animals; Biomarkers; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Drug Stability; Female; | 2018 |
Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA-101 in glioblastoma.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; DNA Modification Methylases; | 2018 |
A Chimeric Antibody against ACKR3/CXCR7 in Combination with TMZ Activates Immune Responses and Extends Survival in Mouse GBM Models.
Topics: Animals; Antibodies, Monoclonal; Antibody Affinity; Antineoplastic Agents, Immunological; Cell Line, | 2018 |
Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
Topics: Animals; Antibodies, Neoplasm; Brain; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Ly | 2018 |
The combination of mannitol and temozolomide increases the effectiveness of stem cell treatment in a chronic stroke model.
Topics: Animals; Chronic Disease; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Disease M | 2018 |
[Establishment of a glioma orthotopic xenograft model based on imaging technology].
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease | 2016 |
[
Topics: Animals; Bevacizumab; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; | 2019 |
Adeno-associated virus 2 mediated gene transfer of vascular endothelial growth factor Trap: a new treatment option for glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cell Line, Tu | 2019 |
Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carbon-Sulfur | 2018 |
Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy.
Topics: Animals; Antibodies; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; Glioma; I | 2018 |
A Simple Three-dimensional Hydrogel Platform Enables
Topics: Aged; Animals; Carcinoma, Renal Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; | 2019 |
Roscovitine effectively enhances antitumor activity of temozolomide in vitro and in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Caspase 3; Cell Line, Tumor; Cel | 2019 |
Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study.
Topics: Animals; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, | 2013 |
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
Topics: Animals; Antigens; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; CD8-Positive | 2013 |
Antitumor activity of (2E,5Z)-5-(2-hydroxybenzylidene)-2-((4-phenoxyphenyl)imino) thiazolidin-4-one, a novel microtubule-depolymerizing agent, in U87MG human glioblastoma cells and corresponding mouse xenograft model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Division; Cell Proliferation; Dacar | 2013 |
Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; D | 2013 |
YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.
Topics: Adenoviridae; Animals; Astrocytes; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferati | 2013 |
The temozolomide derivative 2T-P400 inhibits glioma growth via administration route of intravenous injection.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2014 |
Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell P | 2013 |
Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Azacitidine; Cell Line, Tumor; Dacarbazine; Decitabine; | 2014 |
Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models.
Topics: Animals; Antibodies; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoco | 2014 |
Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movem | 2013 |
Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2014 |
Local delivery of angiogenesis-inhibitor minocycline combined with radiotherapy and oral temozolomide chemotherapy in 9L glioma.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Brain Neo | 2014 |
Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Blood-Brain Barrier; Catalytic Domain; Cell Line, T | 2014 |
Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Models, Animal; | 2014 |
Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models.
Topics: Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Models, Animal; DNA Modification Me | 2014 |
A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dacarbazine; Disease Models, Animal; DNA | 2014 |
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Brain Neoplasms; Cell Line, T | 2014 |
Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-κB signaling in glioma initiating cells.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Transformation, Neopla | 2014 |
Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.
Topics: Animals; Apoptosis; Cell Survival; Chemokines; Dacarbazine; Disease Models, Animal; Drug Synergism; | 2014 |
Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome.
Topics: Adenocarcinoma; Adenoma; Animals; Cell Proliferation; Cell Transformation, Neoplastic; Colorectal Ne | 2014 |
ATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents.
Topics: Age Factors; Animals; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Cel | 2014 |
A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease | 2015 |
Characterization of a novel anti-cancer compound for astrocytomas.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Astrocytoma; Cell Cycle; Cell Line, T | 2014 |
Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Ce | 2014 |
A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Dacarbazine; | 2015 |
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.
Topics: Animals; Blood-Brain Barrier; Cell Cycle Proteins; Dacarbazine; Disease Models, Animal; DNA Damage; | 2015 |
p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regula | 2015 |
Focused ultrasound with microbubbles increases temozolomide delivery in U87 transfected mice.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Anim | 2015 |
Combination of the multipotent mesenchymal stromal cell transplantation with administration of temozolomide increases survival of rats with experimental glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Models, | 2015 |
A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, An | 2015 |
Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Line, Tumor; Dacarbazine; Disease | 2016 |
MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; Female; Glioblastom | 2016 |
Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model.
Topics: Animals; Apoptosis; Benzimidazoles; Cell Line, Tumor; Chemoradiotherapy; Dacarbazine; Disease Models | 2016 |
Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Copper; Dacarbazine; Disease Mode | 2016 |
Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Disease Mode | 2017 |
Expression of dynein, cytoplasmic 2, heavy chain 1 (DHC2) associated with glioblastoma cell resistance to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cytoplasmic Dyneins; Dacarbazine; Dise | 2016 |
Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associat | 2016 |
Specific Inhibition of DNMT3A/ISGF3γ Interaction Increases the Temozolomide Efficiency to Reduce Tumor Growth.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Proliferation; Cell Survival; Cells, Cultured; Daca | 2016 |
Dec1 expression predicts prognosis and the response to temozolomide chemotherapy in patients with glioma.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Basic Helix-Loop-Helix Transcription Factor | 2016 |
The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis.
Topics: Animals; Antidepressive Agents; Antimitotic Agents; Avoidance Learning; beta Catenin; Dacarbazine; D | 2017 |
Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chitinase-3-Like Protein 1; Da | 2017 |
Humanized chondroitinase ABC sensitizes glioblastoma cells to temozolomide.
Topics: Alleles; Amino Acid Substitution; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, | 2017 |
Theranostic 3-Dimensional nano brain-implant for prolonged and localized treatment of recurrent glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line; Dacarbazine; Delayed-Action Preparations | 2017 |
Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model.
Topics: Administration, Intranasal; Animals; Antineoplastic Agents; Blood-Brain Barrier; Dacarbazine; Diseas | 2017 |
β-Elemene Selectively Inhibits the Proliferation of Glioma Stem-Like Cells Through the Downregulation of Notch1.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Down-Regulati | 2017 |
Enhanced antitumor effect of combined-modality treatment using convection-enhanced delivery of hydrophilic nitrosourea with irradiation or systemic administration of temozolomide in intracranial brain tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Combined | 2008 |
An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Biomarkers; Clinical Trials as Topic; Dacarbazine; D | 2008 |
Effects, in an in-vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Carmustine; Cell Line, Tumor; Dacarbazi | 2008 |
Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Death; Cell Line, Tumor; Dacarbazine; Disease M | 2008 |
Characterization of a side population of astrocytoma cells in response to temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; ATP Binding Cassette Transporter, Subfamily | 2008 |
Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection.
Topics: Animals; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain; Brain Neoplasms; Combine | 2009 |
A human brainstem glioma xenograft model enabled for bioluminescence imaging.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Stem Neoplasms; Cell Line, Tumor; Dacarbazine; Dia | 2010 |
Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocy | 2010 |
Trans-sodium crocetinate enhancing survival and glioma response on magnetic resonance imaging to radiation and temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carotenoids; Cell Line, Tumor; Combined | 2010 |
Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Models | 2010 |
Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dacarb | 2010 |
Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2010 |
Enhancing melanoma treatment with resveratrol.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Di | 2012 |
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Chemokine CC | 2011 |
Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model.
Topics: Animals; Brain; Brain Neoplasms; Capsules; Dacarbazine; Disease Models, Animal; Drug Delivery System | 2011 |
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; D | 2011 |
Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Camellia sinensis; Catechin; Cell Line, | 2011 |
Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy.
Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; | 2011 |
Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineopl | 2011 |
An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing.
Topics: Animals; Antineoplastic Agents; Brain Stem Neoplasms; Caspase 3; Cyclin-Dependent Kinase Inhibitor p | 2012 |
The effects of temozolomide delivered by prolonged intracerebral microinfusion against the rat brainstem GBM allograft model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Brain Stem; Cell Line, Tumor; Dacarbazi | 2012 |
Combination hyperbaric oxygen and temozolomide therapy in C6 rat glioma model.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Combined M | 2012 |
A restricted cell population propagates glioblastoma growth after chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Cell Tracking; Daca | 2012 |
Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Calcium Channel Blockers; Cell Cycle; D | 2013 |
Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Dacarbazine; Dise | 2013 |
Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
Topics: Adenosine Triphosphatases; Animals; Cell Division; Dacarbazine; Disease Models, Animal; Guanine; Hum | 2002 |
Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Models, An | 2003 |
Formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with temozolomide: implications for the treatment of low-grade adult and pediatric brain tumors.
Topics: Alkylation; Animals; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbaz | 2003 |
Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.
Topics: Analysis of Variance; Animals; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Per | 2004 |
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Biological Availability; Blo | 2005 |
Artificial tumor model suitable for monitoring 31P and 13C NMR spectroscopic changes during chemotherapy-induced apoptosis in human glioma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carbon Isotopes; Cell Line, Tumor; Dac | 2005 |
Antiangiogenic agent, thalidomide increases the antitumor effect of single high dose irradiation (gamma knife radiosurgery) in the rat orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Brain Neoplasms; Cell Proliferation; Combined Modality | 2006 |
Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin.
Topics: Animals; Anthracenes; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combi | 2006 |
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.
Topics: Animals; Antineoplastic Agents; Benzamides; Blood-Brain Barrier; Brain; Cell Adhesion Molecules, Neu | 2006 |
Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; Disease Models | 2006 |
Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms.
Topics: Animals; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Models, Animal | 2006 |
Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Aryl Hydrocarbon Rece | 2006 |
Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cross-Priming; Dacarbazine; Dendritic C | 2007 |
Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cathepsin B; Cell Line | 2007 |
Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.
Topics: Animals; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Genetic Engineering; Glioma; Magnetic | 2007 |
Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Models, Animal; Gl | 2007 |
An orthotopic skull base model of malignant meningioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Disease Models, Animal; D | 2008 |
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blood-B | 2008 |
Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Proliferation; Dacarbazine; Disease Mode | 2008 |